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PREP'AOE

Cholesterol is one of the most widel¥ distributed
ore!;anic compounds ill animal tissues.
for over two centuries and.

hat~

Altho~

it has been known

been the obj ect of numerous

chemical and biochemical investigations,

maD¥

functions of

cholesterol are still not completely understood.
Today, cholesterol is bains implicated as a patho&en

!.!:!!:. g.eneris. It has been known to be

a constituent of t;all-

stones ever since the compound was first mentioned in the 18th
century. It is speculated that it

m~

play an important role

in the etiology of cancer and atherosclerosis.
In the populQ1' mind, cholesterol and atherosclerosis
are resarded as almost sjDonymous. Although a connection between
the two seems definite, the extent of the

is still

relationshi~

controversial. The implication that cholesterol is an

import~t

factor in the etiology of atherosclerosis has come from
consistent observations that this syndrome is prominent in
states accompanied by hypercholesterolemia. The most important
of these states, by virtue of its prevalence, is diabets
mellitus. Literature data on diabetes mellitus shows very
conclusively that there is an increase in the incidence ot
atherosclerosis among diabetics.
iv

With the discovery of insulin and the oral

hy~ogly-

cemic compounds, some of the effects of diabetes mellitus have
been controlled. There is, however, still a

que~tion

as to

whether the accompanyiD.b hypercholesterolemia is reduced by
these 8sents. Since many investib8tors believe that if the biosynthesis of cholesterol is controlled, the blood cholesterol
will also be controlled, a study was Ulldertaken to elucidate
the effect of the

h¥~oSl3cemic

compounds: tolbutamide, phen-

ethylbiguanide, cp!orpropamide, and ,metahexam1de. on cholesterol
biosynthesis

!a

~v_l_tr_o_.

Recently it has been reyorted that procaine therapy
was effective, among other things, in the treatment of high
blood pressure aJld heart disease. Therefore, the efiect of
procaine (p-aainobenzoyldiethylaminoethanol) on the biosynthesis

-

of cholesterol in vitro will also be studied.

v
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HIHTORI

The compound known as cholesterol was initia.l..i.J'
described in the first half of the 18th centur3- As early
1753, Vallisnieri (237)

reco~n1zed

8.8

that ball-stones were

soluble ill alcohol. De Fourcroy (71) in I'lB:j mentioned that
PolJ.etier de la Salle isolated a constituent of gall-stones
some twenty .:rears earlier

an~

Showed that the substance iso-

lated could be obtained as wb! te cr'ystalline leal'lets i.·rom
alcohol. De It'ourcroy (71) isolated a

1ar~er

quantity of the

alcohol soluble substance, whiCh he believed was the same as
spermaceti and that it was related to "adipocire", a matter
obtained fro", acid tre;J.tment 0:1' grave wax, a substance formed
in moist places in cementaries duriDb decomposition of tue
bodies.
Gren and ConL'a.di (60)(102) confirmed this fact and
recognized tllat the same constituent

01'

sall-stones coul;1 be

obtained bJ ether extraction as well. Chevreul (>j) in 1815
showed that the alcohol soluble substa.nce obtained from bal1stones was dit'lerent from spermaceti and ftadi,eJocire tl by virtue
of its beinb unsaponifiatle and that its

meltin~

point was

2

different. He

~ave

this substance tile oribinal

cnolestrine from the Greek: chole, bile; and

desi~atiun

!!~,

01'

solid (54).

With the knowledt!)e that cholestrine is found in the
unsaponifiable portion of fats, it was

subse~uQntly

identified

as a constituent of human and animal bile (97), tumors

(1~9),

hwnan blood (3d), brain (06), and e6t5 yolk (1,,0). Thereat-teL'"
cho~estrine
an~ma.l

of

was

reco~nized

as a normal constituent of all

cells and several secretions, as well as a comjJonent

patnolo~ical

deposits

(168)(~~~).

The fact that cholestrine

had an esterifiable hydroxyl brouP was shown by Berthelot (24).
At that time the name of the compound was changed to the more
descriptive "cholesterol." Cholesterol esters of oleate and
palmitate were isolated. by Hurthle (111) in 1896. In 1909,
Rosenheim and Tebb (200)

four~d

palmitate and stearate esters

of cholest.erol in normal adrenals. 1l he fact that cholesterol
is deposited. in atheromatous aorta as tne
~Jindaus

este~'

was shown by

(257).

In 1846, Gobley (9b) showed that cholesterol from
e~bt

~al~

;l1eno:t.zi

and bile was identical. This was later confirmed by

(l!)~:.n.

The existence ot: a d.ouble bond was indicated

when Wislecenus and Moldenhauer (260) succeeded in
a dibromide derivative of

chole8te~'ol.

~reparlne

The :first exact empirical

formula of cholesterol was achieved by Helnitzer (191) in

3
1888 from the analysis of' cholestel.'yl acetate dibl.'oJilide. The
conversion

01'

cholesterol to cholestanone, car.ciad. out by

Diels and Abd.erhalden (72), proved that the alcohol group is
secondary.
The elucidatioll of' structure was due to the work of
\dndaus (.2.58). Aided by the studies of Wieland
related bile acids, Windaus
tive formula, which in

(2~c:)

on the

(258) in 191j arrived at a tenta-

1932 was changed to the one now accepted.

Evidence leading to t.he correct formulation was prvvided by
several workers. The new formula was based on X-raJ' studies
by Bernal (26) and the finding of chryselle by selenium de4Ydro~ena tion

of cholest erol. i'rom Diel' s and Bernal' s f'inJ.ings,

Hosenheim and. King (198) sUOf;.>ested a perhydrochrysene
structure, and later on the finding of' "Ueland and Dane (2,52)
in rebard. to the size of rine B, the cyclopentano.tJerhydrophenanthrene st.z:'ucture was adopted (198) (1)'1) (2.52) to 1'1 t the
data.

CIlliMICAL

h.l!.ACl\r01~S

Since most of the reactions of cholesterol occur at
the hydroXSl

~rou~t

at the double

bon~,

or at carbon

7,

the

chemistry of cholesterol is not very involved. An understandi1l6 of a lare;e number of reac tions 01' cholesterol involves
a cOl,sideration

01'

the conformation of trle molecule. The

4

conformation of

chol~titerol

was suggested by Barton

(l~)(lo)

based on the conformations of cyclohexanes. The chair form of
cyclohexwle i8 thermodynamically more

stabl~

(21) and in this

conformation two types of: carbon-hydrogen bonds are evident.
The bonds joined at
rin~

ri~lt

angles to the

~eneral

plane of tile

were orie,inally cal.ied "polar" but are no'W. referred to

as "axial" anl.1. those that are in the general plane ot tlle ring
are called "equatoL'ial u (17).
The equatorial position is more reactive in reactions
depending upon the accessibility ot a substituent, su.ch as in
esterification and hydrolysis. Heactions dependinb upon an
attack at the hydrogen atom proceed more rapidly when tne
hydrogen atom is equatorial. Ionic elimination reactjons
proceed more rapidly with the elimination of two axial
substituents from adjacent carbon atoms.
The hydroxyl

grou~

of cholesterol beillB

e~uatorial

is freely reactive. It forms esters, and ethers; it may be
oxidized; it may be replaced by haloben; and it can be removed,
under certain conditions, as water. The dehydration of cholesterol was i.rutially reported. by

;~uthner

and Suida (155).

Action of strong acids may cause polymerization of cholesterol
to bis-cholestadienes (40)(189).
Oxidation

oi.'

Cholesterol to cholestanone may be

5
achieved by the 0pj;enauer metiJ.od (1,(4), or by heatillti alone or
in the presence of a suitable metal catalyst (ljb). :t'he esterification and etherification of Cholesterol may be achieved
~hen

conventional methvds.

oJ

cholesterol is treated with thioD3l

chloride or phosphorus pentacnlorlde, choleste.L'yl chloride is

formed (73)(152)(155).
The double bond in cholesterol undereoes the usual
aJ..iition reactions. The .bydrogenatioll of cholesterol over

platinum yields onlJ cnolestunol (2;;5). It has been known :t'or
many years that cholesterol forms a dibromide (lj2) anti a

di.chloride (1;';», but that

t\\O

isvmt.:ric dlhn11des JIJUV be

obtained. 1s a fairly recent obsel:vation
:t'he routes of formation
to involve the

01'

(lts)(1:J)(20)('~»)(1)o).

the cholesterol dihalidos a.t.J,tlear

anti-f~Kownikorf

additiun of !lalide to an

interr.'1ediate halonlum ion sUt!,gested. by }'leser (85) and

co.n.firmed. by Barton

!l!!. (20). The brumination

was formulated as involv1ne a rear

alpba-bromonium ion.

~he

3. l

cllolesterol

and ilsoion ot an

double bond of cholesterol 1s also

reactive toward oxidizing agents
Be~lD6anate

a~tack

01'

oxidation

~iv1n~
~ives

diols or oxides.
the 3-beta-5-alpha-b-

i)hd-triol (cis h,)'dl.'ox,ylation) (2)6) as d.oes osmiwn tetroxid.e,

i\hose complex with cholesterol haB been iSOlated by

t,.ee (68)(2;u).

~ihtfn

(.;.1'18-

hydL'ogen peroxide, performlc. or jleriodic

6

acid is uHed, trans hydrox,ylation is observed (8b)(j'j)(I.;jO).
uxidation 01' cholesterol dibromide by acid. permanganate yields
prot:;,esterone and cll.olestanone (21')).
Bromination of cholesterol at carbon

? (beta) may

be obtained boY using N-bromosuccinimide <.,0) (2u-;J) or by
irradiation of chloroform solution of cholesterol and.
bromine (208)(20'::1). Under proper conditions N-bromosuccillimide
will also yield eholestane-3-beta-5-alpha-diol-6-one. The
7-bromo compound 1s of great

interes~

in

~hat

it can be de-

hydrohalogenated with dimethylaniline (47) or collidine (27)
to yield ?-dehydrocholesterol which

~ives

vitamin Dj after

irradiation.

~,hen

isotopically labeled acetic acid is administered

to an animal, or 1s added to the incuLatioIl medium of tissue
~reparations,

isoto~ically

labeled cholesterol can subsequently

be extracted from the organs of the animal or fL'om tne tissue
pretlarations. This, essentially, was the discovery re,I/OL ted b.r
Bloch and Rittenbere; (3;') in 1942 and Bloch, Borek, and Rittenber6 (34) in 1)40. After a number of isotopically labeled
substances were similarly tested, it turned out that labeled
cholesterol arose on13 :from those that weI'e known to 'be meta-

7
bolized via acetate.
600n after the originul discover., of Bloch and
hittenbert; (35) was made, Little and Bloch (137) showed t.l:lat
both t.l...e side chain and the nucleus of

choleste.L~ol

aC'iuired

the label from isotoklic acetic acid aud that botn carbon atoms
of the acid we.l.'e used for synthesis. They fed doub1.1 labeled
acetate (C14H3c1302:Na) to rats and lou.nd that the ratio of
Cl4 to C13 in the synthesized. cholesterol was about ;;:4.
Assuming toot all ttl.e carbon a toms of choles I..e,,'ol were deri veel
from acetat..e, the result sUr;..tJested tnat of tJ..e 27 cW:'bons of
cholesterol, 15 were derived from the meth.Yl and. 12 :.r.i.'om the
cal:box.Yl atOJll of tile acid. The hypothesis was later confirmed
by

chemical debradation of cholesterol

synthesi~ed

by

using

radioa.cetate labeled. first in the methyl 'pOSition and then in
the carbox'yl position

(53)(54)(3~)(bj)(70)(204)(206).

t:;;roups of carbon atoms 01' cholesterol shown to be

The two

de~"i ved

from

tile carboxyl and from the methyl carbon of acetate are represented in (1) by "C" and

Itltll"

resJ)6'ct1vely.

8

Although the ini'orrllation about the individual enzymes
conc(;rned is meati>er, it is now possible to outline most 01' the
reactions 01 sterol biosynthesis form acetate.

~ith

the inter-

mediates betlJH. en lanosterol and cholesterol beine:, ommitted, the
mown biosyuthetic se'tuenca in the :formation of cholestex'ol
from acetate is swnmerized. in Scheme I.

~allce

bot.h aceto-

acetyl-eoA and mevalonic acid are intermediates in cholesterol
sjnthesis, substances which directly or indirectly contribute
to the formation of the twv intermediates are also included
in the scheme.
There are three places in the cholesterol
where a repeating pattern of five carbon atoms,

molec~le

containin~

acetate meth31 and carbox,yl atoms in an isopentane structure
can beseen.

This fact was first recognized by Bloch (266)

after debradation of the side chain of cholesterol biosynthel4
sized from c -labeled acetate, and prompted him to revive the
old hy-pothesis that sy,ualene (II), a dihy'drotriter,tJene, is an
intermediate in cholesterol biosynthesis (32).
(;
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Squalene had been

sUb~ested

as beiD6 involved in the

biosynthesis of cholesterol as early as 1926 by Heilbroll, Karum
and Owens (105). This was supported by Channon (51) who found
an increased cholesterol content in the liver ot rabbits which
were ted squalene. The first experimental j,Jruot that; sy'ualene
was a j,Jart 01' cholesterol biogenesis was obtained
and Bloch (128) who showed that

s~ualene

byLan~don

was synthesized by

rat liver from acetate. The conversion of squalene into sterol
has since been confirmed by Aaudbal',Tchen and Bloch (154)
who obtained the conversion of

s~ualene

into lanosterol.

The torei:)oine) discussion slUumarizes the known biosynthetic pathway of cholesterol to 195b. The rec06Ilition
of the pattern of acetate carbons in the isoprenoid units
stimulated extensive research on the ori"in
of C5 and. Cb
t)
branched chain acids as the source of isoprenoid units used
in the biosyntnesis of squalene and sterol. A number of known
branched chain aCids, such as 3-hydroxy-'-meth3l glutaric
acid (HMG) , 3-methylgluconate, iso-valerate, and 3-methylcrotonate, were implicated in the b10synthetic pathway, but
nOlle 01 these provided positive proof" 01' the idel.l.tity with

an illtermediate

betw~en

of 3-h3droxy-3-met4J-l

acetate and squalene. The synthesis

~lutaric

acid

(l~G)

from acetate was

demonstrated as early as 1952 by Bloch (32) and ulthoU6h it was

11

proposed as early as 1954 by Rudney (202) as a possible intermediute between acetate and squalene, it was only after the
discovery of mevalonic acid that the asymetric mOllocoenzyme A
ester of 3-hydroxy-3-metbyl gll.ltarate, not the free acid, was
recognized as its precursor.
The discovery of mevalonic acid was the result of
research related to bacterial metabolism and not to cholesterol.

-contained a factor which could

]olkers et ale (202)(263) found that "distillers 801ubles''

the growth of an

repla~e

acetate-requirin~

Acidophilus. When isolated,

~he

acetate in

sup~ortin~

mutant of Lactobacilus

factor proved to be the

lactone (Ill) of the opticallT active

~,5-dihydroxy-3-methJl

pentanoic acid (IV) and was named mevalonic acid. The resemblance of the acid (IV) to 3-bydroxy-3-methyl glutaric acid (V)
~ave

rise to the speculation that it might be involved in the

biogenesis of cholesterol. Finally, Tavormina, Gibbs and
HO, ",OR,

H21

/0,

yH2

H2 0 , / 0 • 0

o

(Ill)

(IV)

(v)

Huff (;227) showed that rat liver hOJa06ena.tes which were

12
relatively inefl icient convel'ters of acetate to choles \"el'ol
14
were able to convert mevalono-la.ctone-2-C
almost quantitatively to cholesterol. The rest of the chapter will deal
witn the discussion of the individual steps that leaJ £rom
acetate to cholesterol.
J~ctivati()n

of acetate to acetyl-CoA and condehsation

of" this to acetoacetyl-GoA are well established reactions
~hich

are not peculiar to cholesterol biosynthesis. liihe next

stage, a condensation of acetoacetyl-poll. with acetyl-CoA, has
been studied by Hudney (20;) and Lynell (14,). The enzyme
responsible for the reaction,

HMG-CoA-condensin~

enzyme, has

been partially purified from yeast (84). The process liberates
one molecule of coenzyme A, which comes :from tile acet.!l and
not the acetoacetyl group. (llhe product, -,-hydroxy-3-methyl
elutaryl GoA (HMG-COA) is formed as shown in Scheme 11. The
reaction is not easily reverSible, but HMG-CoA can be irreversibly cleaved by anothe,c enzyme t HMG-CoA cleavage enzyiIle t
to acetoacetate and acetyl-CoA (203). This, in eflect, produces
a hydrolysis of: acetoacetyl-CoA and is thought to produce :free
acetoacetate in the liver (11).
The synthesis of ID4G-COA does not come
from acetate.

jl.llothe~"

potcnti:.d source of

H,,1G-CoA

e~clusively

is the

biotin-dependent enzymic carbox¥lation of 3-methyl-3-hydrvxy-

13
butJr31-CoA and 3-methylcrotonyl-GoA (02). Bince both of these
substances are metabolites of leucine, the amino acid is a.
distant precursor of cholesterol. The incubation of leucine
or leucine metabolites and carbon dioxide with rat l.iver
ho.tlloe;enates does yield cholesterol (31).
The synthesis of lliAG-CoA to mavalonate by a soluble
enzyme system from yeaut has been reported bJ Durr, Rudney and
J!'ert;U80n (77)(83)(204) and by !;ynen (141)(146). It is aptJarently
catalyzed by a single enzyme,

~G-Co~

reductase. The enzyme

contains sulfhydryl groups essential for the catalytic activity
as indicated by the severe inhibitory ef1ect of p-hydroxymercuribenzoate, and the requirement of

ad~ed

thiols to

maintain the activity of the purified enzyme. l."or every mole
of HJ.llG-COA reduced t one mole of mevalonClte is formed t two
moles of

TPh~

are oxidized, and one mole of coenzyme A is

released. The reduction of HMG-CoA was shown to oCGur on the
thiol-esterified carboxyl group. Mevaldic acid (VI),

~hicll

was

HO, /CH3

c

H2Y

/".

CHO
previou.sly

~resumed

to be a part

7H2

(VI)

C02H
01'

cholesterol biosyut.i.lesis
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was

~roven by

Durr and Hudney (76) not to be involved.

The :t'act that the :t'ret:: aldehyde, mevaldic acid, is
not an intermediate in tne reaction does not pl:t!clude the
pos~ibility

tbat mevaldic acid is an intermediate in the bio-

synthesis of cholesterol. The possibility that enzyme-bound
mevaldic acid or its thiohemiacetal are intermediates still
remains. Although free mevaldic acid is not an intermediate in
the reaction, tAe conversion of mevaldic acid to mevalonate
can still occur through a side reaction. l!'or exampl.e, Durr
and J.(udney (76) have observed a TJ?NH-dependent reduction o:t'
mevalonic acid in certain yeast preparations, and
has reported the presence of a
hydro~enase

DPNH-de~endent

Johns~one

(118

mevalonic de-

in yeast. The products of these reactions have not

been identified.
Schlesinger (211) has reported a DPNli-dependent
mevaldate reductase yielding mevalonic acid. This coUld explain
the reports of Wright !1

~

(265) on the biosynthesis of

mevalonic acid from mevaldic aCid, and. also the
SChunk at ale (21;)

ti~t

findin~

of

unlabeled mevaldic acid depressed the

incorporation of labeled acetate into sterol. The overall
reaction, therefore, probably proceeds in a two step manner
with an enzyme bound mevaldate or its thiohemiacetal being
an intermediate in the reduction. It is

ap~arently

catalyzed

15
by a sir.ible enz.rme. Severa.l
be catalyzflid by a

sin~le

t~o-step

reactions are assumed to

enzyme, and. such reactions apparently

yroCeed through enzyme bound intermediates

(l'l2)(~lQ)(~2o).

The striking feature 01' this reduction is that it
is iI'reversible. Attem,Pts to reverse this reduction have not
been successful (18u)(195). HMG-CoA red.uctase, whatever the
source, is stereospecific for the natural opticul enanthiomorph
(+) of H~G

(83). Interestingly, all the early

sterol biosynthesis are

electro~hilic

sta~es

of chole-

reactions at a carbonyl

6rouP, akin to Aldol condensations, with coenzyme A playing
its normal biochemical role 01' enhancint;; the electron deficit
at the carbonyl carbon. As far as it is known, once mevalonic
acid is formed t coenzyme A is no lont-er required for furti.ier
reactions.
The second phase of the biosyntllesis of cholesterol
involves several enzymic reactions which convert mevalonic acid
to squalene. Most of these reactions are s.t/eculCtive and only
a :few of the enzymes involved have been isolated and purified.
As a preliminary step to the investigation of the coenzymes
involved in tile conversion oJ:. mevalonate to squalene, FopJak
and Cornforth (18)) examined the various fractions of homoe:;enates obtained by centrifut<;at10n. liost 01' the enzymes neceeseary for cholesterol and. squalene synthesis weJ.'e f'ound to be
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in the mic.t:os01l1e8 (8104 fraction) and in the supernatant
obtained from the 8 104, fraction. After the precipitation of the
proteins in the Bupernatant, f'ollowed by reconsti tu l.i01:' of the
proteins in 0.02 M potassium hydrogen carbonate and by dialysis,
most 01: the ellzymes neccessary for the hio synthesis of'

s~ualene

and cholesterol are obtained. Together with the microsomes,
the dialyzed 8 104 supernatant was able to incorvorate mevalonic
acid into squalene maxil1:lally. However, D.PN, Tl)N, and ATP had
to be added to the incubations,

othe~wise

no incorporation of

mevalonic acid into squalene could be obtained. The microsomes
are neccessary for the synthesis because they c ontain an

~m

compound, hiehl.1 sensitive to oxidation, and which is essential
in the reactions preceding the formation of squalene.
The fact that the liver enzyme sys"ems required ATE
:tor the conversion of' mevalonic acid into squalelle sUoe,ested
that phosphorylating reactions were involved in the biosynthesis.
T1Jhen (228) was the first to report the formation of 5-vhos'phomevalonate (VII) from mevalonic acid and AT.P using a yeast
enzyme prevarat1on. The same reaction was also identified as
taking place in I'at liver pL'eyarations (195) (2i tO) (2i H).
Tcllen (2.;:>j) partially purified the enzyme by treatment of a
\ hioh speed supernatant o:f yeast 8utc:alyzate with .protamine,
followed by fractionations with ammonium sulfate

aIhl

calcium

18
phosphate

~el.

The product that was formed

~fter

the phospho-

,- '1)~ in a ratio of 1:1 when mevalorylation contained (.; I'+- and P'
nate-2-C14 and A'rp32 was used. Direct chemical analYBis of the

substance isolated from the liver incubation also showed that
it contained one atom of phosphorus per molecule of the product (212)(240). Since it gave no hydroxamate and was stable
to alkaline and acid hydrolysis (212)(228) and since the free
acid failed to lactonize (141)(212), the must probable structure
appeared to be that of

5-~hosphomeva~onate.

The identity of the

phosphorylated product was finally established as 5-phosphomevalonate by chemical phosphoI71ation ut· wcvalonic acid (87).
t,levalonic acid, therefore, by the action of mevalonic
kinase, is .vhosphorylated to yield 5-phosphomcvalonic acid.
The enzyme involved in the reaction seems to be an 8H-enzyme
since it is inhibited by p-chloromercuribenzoate. dlevalonic
kinase, whether from yeast or Ii vcr t 1s stereospec.ii'ic for the
natural enantiomorph (+) of mevalonate just as H.MG-GoA. reductase
was stereospecific for

(~)

HMG-GoA. The liver mevalonic kinase

cannot phosphorylate mevalonic acid lactone or the 3-anhydro
analot:jues of mevalonic acid (132)(153). When 5-vJ:lOS.t>ho-(2-C14 )mevalonate is incubated without AT?, there is no iJroduction of'
sterol. This
Althou~h

s~bested

a further phosphorylation takes place.

a further characteriza.tion of' the substance is needed

tne next intermediate seems to be
acid

(!:I5)(21~).

5-diphos~homevalonic

The enzyme catalyzillt5 this reaction has been

partially purified from pig liver by

l~pjak

au~

(106)

the reversible fOrtllation of 5-dij,)hos!-,llomevalonate

!L'Olll

catalyzes
1Jhos,!,)ho-

,

mevalonate and ATP. The positivn o:r eq,uilibrium lies on the
siue of t.ne forward reaction and. 60es at o,.>timwn rate in the
presence of Mg++ ions. As the phosph omevalonic kinase reaction
is reversible, it is evident that the second

~!lOs.t:>llate

5-diphosphomevalonate is an enerbY rich bond, probably

bond in
01'

the

same order of magnitude as that o:f ATP.
5-Diphosphomevalonic a.cid, by the catalytic action of
di~h081Jhomevalonic

anh3drocarboxylase, is then

tr~sformed

isopentenyl pyrophosjlhate (3-meth.Yl'but-}-en-l-yl
VIII) wi til the loss of one molecule ot'

(;Oc~..

c.

into

'p'yrovhos~hate,

The decarboX.flation

seems to proceed via a labile phosphate ester,

~-di~hos"pho-3-

-,~2 contain~d
in tn' e Am,3~
used
,tJhosphomevalon:J.te (IX) t since .P'
...
.rin tne reaction did not apjlear in the isopentenyl pyro»nosphate (55)(144). This compound, isopenteny1 pyrophosphate,
a uecax'boxylation product of 5-diphosi-/hOmevalonic acid, must
'be considered as the substance

Wlder60in~

conu.ensd. tion to

squalell8.
Al though the formation of iso1,..'entenyl .i.Jyrophospl.l.ate
and 1 ts incoI'poration into the s\.lualene

mol~cule

has been proven
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to take place (144), the maruler in which this takes
still a subject of wiele research. Since at
s~ualene

molecule the

~roupin~

~lace

two ends

tlHl

is

01'

the

appears, it

(CHj)2C • CH -

follows that an isomerization of' the isopentcn;yl pyrophosphate
to

a

dimethylal.iyl structure must occur at

SOUle

stac;e. \;ith

the partial pUL'ification of' the enzyme isopentellJl PYl.'ophos,Phate
isomerase (144), which converts isopentensl pyrophosphate to
dimeth31allyl pyro,Phosphate, the hy,Pothesis otthe isomerization
of isopentenyl pyrophosphate was exverimentally proven. The
reaction could be envisioned as beillb initiated by a proton
followed by an elimination of a second proton from the molecule
as shown in Scheme IV.
The ssnthesis of squalene proceeds from a series of
condensations invol.ing electrovhilic addition to doubly
metnylene

~roupa.

Dimetb31allyl

boUl~

has the properties

pyrophos~hate

in com.Hon with other substances in which a hydroben, a hydroxyl,
or an esterified hydroxyl (in this case esterified with a pyrophosphate) is in the alpha position to a double bond. hliUlination :from such substances may oct..!UI,' readily,
electron deficient species is
between two equivalent forms:
( ...... C= C="' ....... )+

./

I

'"

+

OR-

par~1a~ly

1'01'

stabilized by resonance

" O=O-O-OR
I

,,/

---~,

I

I

'C=O-C4'

/' ! "
~

-fC-O=C

..."...

tIle resultint;>

.".,

.........
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The allene type substances are strono electrophilic l.'ea.c:.ents
and could 8.'ttack a terminal methylene group. This electrophilic
mechanism could occur either via the

interm~diate

ion or as a

billloleculal.' displa.cement.
The most probable first condensation leadines to the
s'yllthesis of s,-,ualene, therefore, is bet.Vween dimetLyla11.ll
P5rophosphate and isopenten,l
elimination of

pyro~hosphate

~yro~hosphate

(143), with the

ion from the dimethylallyl pyro-

phosphate (Scheme IV) by a mechanism just described. 'l'he condensation product, of course, carx'ies an excess of ,positive
charge, but stabilization may occur by elimination of" a proton,
among other ,possible processes, givine; rise to t;;eranyl p:/rophosphate (14}). In geranyl 'pyrophosphate we have

a~ain

an

electrophilic reagent, which can condense with another molecule
of isopentenyl pyrophosphate in the same manner as the condensation of the

la~ter

with dimethylallyl

pyrophos~hate.

Again

by stabilization through elimination of a. lJroton, the product,

farnesyl pyrophosphate (14}) is obtained.
It is not known whether the two condensations are
catalyzed by two different enzymes, but the formation
geranyl and farnesyl

pyrophos~hates

a liver enzyme system.

~en

!1

~

01'

is readily demonstrable in
(144) BYIlthesized dimethyl-

allyl pyrophosphate and geranyl pyrophosphate

and

obtained the
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ISO.PENTEl~IL

PIHOPHub.PHA'r~

PIHOfhOSPHA'l'E TO GblRAN:iL

1. Isomerization of isopentenyl pyrophosphate to dimethyla11yl
pyrophoshate:

2. Formation of geranyl pyrophosphate:

C~C/CHj
II

Cll

I

CH2
)

)

I
I

Cli.,
c,;

C - CH.
II
:;

eH
I
CH20P20&li;
geranyl
pyrophosvhate
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formation of geranyl ana farnesyl
system

pre~ared

trom yeast and

pyro~hos~hates

~rom

with an enzyme

soluble supernatants of

liver homogenates.
Ifarnes,yl 'pyrophosphate t a Cl ,5 iso,Prenoid su.bstance,
resembles squalene in the fact that a tail to tail condensation
of two molecu.les would give rise to squalene. Tne

a~~earance

of

nerolidol (X)(l84) in incubations of liver enzyme sJstems tiave
rise to tl. .e speculation that farnesyl !>yrophosj:l.o.ate undergoes
isome.cization to nerolidol pyrophosphate witll the two substances then condensiD6 in a tail to tail condensation

yieldi~

s,,!ualene as the pL'oduct. The enz.yme responsil)le I'or the isomerization haG not been isolated. The conclusion that the
reaction is a genuine enzymatic formation of the nerolidyl
deriva'tive rests on the appea.l'ance of free neru.Lidol after
hydrolysis ot' a mixture o:f polyprenol derivatives with snake
venom phosphatase and also from the reduction of a :freeze-dried
alkaline specimen of these derivatives with lJiAlh4 in ether (184)
It seems certain, therefore, that there exists an
isomerase which if;oLlerizes the farnesyl pyrovhosphate to
nerolidyl pyrophosphate. The isomerization probably proceeds
as a result

01'

inteL'Ilal phosphate rearrangement (Scheme V),

althoutf)l se,Paratiun and reattachement of
constitutes another pOGsibility.

p'yro.tlhos~hate

ion
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SCH~l~

1. Formation of farnesy1

V

~yrophosphate:

farnes,yl
J,)yrophosjloote
2. Isomerization of farnesyl pyrophosJ:,)hate to neroridyl
phosphate:

lJYl.'O-

R -

0'-

nel.'olidyl PYL'ophosphate
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By a previously discussed electrophilic process,
farnesyl anJ nero1idyl

pyro~hosphates

could condense in a tail

to tail condensation. The mechanism of this reaction has been
theorized by Pol>Jak and Corn:forth (184) and is t<;;iv8n ill
clcheme VI. It involves the elimination of

~'yroJ!hos~h"",te

subsequent electrophilic attack on nero1iJy1

pyro~hosvhate.

The product, a hypothetical electron de£icient
which still contains the

pyrophos~hate

with

intermedi~te

of 11e.1'olio.01, could then

become s1;ubilized by elimination of a proton, the

pyrojJhos~lu te

ion, and another proton to yield dehydros-iu,alelle.

Althou~h

debydrosqualene has

no~

been directly implicated in the bio-

syn.thesis of cholesterol, it seems likely that it is an intermediate since DPIHl is needed in the conversion of mevalonic
acid to squalene (195).
Recently sUPJ!ortlng evidence by Hi11iu6 and 1310ch
(1':15) sUboests that the .b..Ypothetical condensa.tion of farnesyl

and nerolidJl

pyropnos~hates

as postulated by PopJak and Corn-

forth (184) is 'pJ:'obably true. Their results indicat;e that out
01'

tile 12 jlossible deuterium atoms from

(5-D~)-w.eva1ona te,

only

10 wel.'e cunt.ained in the molecule and the 2 t1..lat dissappeared

were lost from the two central atoms of squalene.
The relationship

betwe~n

squalene and lanosterol has

been 'previously discussed. 'rhe cyclization of sy,ualeno to
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lanosterol is catalyzed by the enzyme squalene oxiJ.ocyclase I.
'I'lle ini'Giating species actin6 on squalene is

aSSUlaeu

to be a

cationic oX.I't;;,en atom, e.b. OU+. The assumption comes from the
fact that

WIl.en

mevalonic acid is incubated with rat liver

homogenates under an atmosphere ot nitrogen only

s~ualene

is

synthesized. \\hen oxygen is substituted :for nitrot)en, cholesterol is almost the only product that can be isolated with.
very little squalene (185).

By

attackin~

one of the terminal double bonds it

creates a new cationic species which attacks the next double
Dond, thereby producing a six-membered rino. The
attack continues in the same manner until the

electro~hilic

~artial1'y

cyclized

cation-olei'in complex Xl t Hcheaa VII, is 1ormed. The complex
undergoes :further rearrangement to give complex XII. The
formation of lanosterol is completed by m.it;;ration of two
hydrogen atoms and by the expulsion of a proton fl.'om 09 to form
the double bond at

°

8 - 9 - The evidence for these rearranbements

has been provided bJ' isotopic labeliIl6 obtained '0.1
Tchen and Bloch (154) and by

Corn~orth

!l

~

A~iawlt).,a.l,

(bj)(b4).

The cOIlversion 01' lanosterol to cholt:sterol proceeds
by a series 01' steps, not all 01 whiCh have been wOl.'.k:ed out as
yet. The 1'i.rst 01' these reactions is tile oxidative removal of
three meth.Y 1 groups from lanosterol (j4). 'ilhe reaction seems
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to proceed via the carbox3lic analo6ues which are then decarbox.ylated to ,yield :> molecules of c.;02- 'I'he ordeL'

01'

tI.. e removal

oi' the methyl groups from positions 4 and. 14 is still unknown.
After tne removal ot: t,ile three Illeth.11

gl.'OUpS,

the ..1ouble bond

at 8,,, .1.s replaced by a double bond at 5,6, :1' ollowed

'b:t

the

removal of tna double bond in the side chain of lanosterol.
~ince

this portion of cholesterol biosynthesis is still very

uncertain, the reactions leading from lanosterol to cholesterol
will not be discussed. A general pathway o'btailled .from 'preliminary experiments is shown in Scheme VIrl.
Cholesterol is, therefore, entirely synthesized from
acetate. By what appears to be an irreversible reduction of
HMG-CoA in active equilibrium with acetate, mevalonic acid is
formed which 1s then conversted into 1sopentenyl pyrophosphate
having both nucleophilic

ar~

electrophilic activity_ Utilizing

both of these activities the,y 6ive rise to intermediates
(6eraD3l and tarensyl

pyro~ho$phates)

by a head to tail voly-

merization. Farnesyl pyrophosphate then undergoes isomerization
to nerolidsl pyroptlosphate, which then are somehow joined tail
to tail to produce s",ualene. Sli.ualene retains nucleophilic
activity, cyclizing to lanosterol, which eventually, by a
series of reactions, produces cholesterol.

CHAl?Tl£R I I

Diabetes mellitas is a chronic metabolic disorder
characterized. by a disturbance of lipid and carbohydrate metabolism and manifested by a decreased tolerance to carbohydrate.
The cond.ition develops either when the production of insulin
is inadequ.ate, or when the action 01' insulin on tnetissues is
antagonized.
Many facts led. to the belief that the vaD.creas
produ.ced a hormone which was

neccessar~

bolism of carbohydrates. In 1889, von

for the norJJlal meta-

Meri~

and. Minkowski (160)

showed that the removal of tile pancreas caused diabetes mellitus
It seemed likelT t.l:w. t tl,e ductless Islets

01'

Lant::.erhans, whic h

lie imbedded in the body of the pancreas t were tL.e source of
a secretion, whose absence caused the syndrome. De Meyer (101)
in 1909 8U6sested the name insuline for the hypothetical
internal secretion of the 'pancreas.
It was not Wltil 1922 that BantiD.6 and Best (12)(1,)
(14) succeeded in extracting a preparation from normal pancreas
containing the antidiabetic hormone in a form which consistantly
alleviated all manifestations of diabetes in totally depaD.crea-
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tized dogs. In 1926, crystals ot insulin were isolated from
pancreatic extracts (1).
Insulin is a polypeptide which is rapidly destroyed
by enzymatic action in the gastro-intestinal tract. Although

attempts have been made to protect the insulin from beino
dieested atter oral administration, preparations

givin~

ade-

quate absorption when administered orally have been unsuccessful
Daily inJections are needed for patients witn diabetes mellitus
in order to maintain good health. Since it has been found that
the action of insulin 1s influenced by the size ot the crystals
administered (253), different preparations have been made
utilizing zinc auspensioDS, protamine suspensions, amorphous
zinc insulin, and different combinations of the above (71).
By using different ratios of these preparations,
almost any desired duration and strength ot action can be
attained. Nearly maximal progress has been made with this type
of therapy. Benefit would obviously be derived if the

~ancreas

could be stimulated t. increaae the secretion of insulin by
orally ad.Dl1nistered. co.pounds, or if the orally administered
compounds could imitate the action of insulin in the treatment
of diabetes mellitus.
HISTOHY 011\ ORAL HYPOGLYCEMIC CO.MPOUNDS

FlYer aince the isolation of insulin, a search for oral

34hYpoglycemic compounds has been in erfect. In 1920, Frank,
Nott~

and Wagner (90) reported the

hy~glycemic

effect of a

diguanide. 81llthali.n. Graballl and Linder (100) studied this
compound and found that it caused severe liver damage

and

it was

soon abandoned as a hypoglycemic compound.
Plant extracts have been used. a long time as remedies
for diabetes mellitus in maD¥ parts of the world. For example,
Allen (12) investigated.

blueber~

leaf extracts and Hugh-

Jones (110) studied the extracts of periwinkle, mistletoe, and
nicker berr7. Many other plants possess marked hypoglycemic
properties. The two alkaloids, galepine (1&8) :from tile seeds
of GaleRa otficinalis, and 1apanine (58), trom the seeds of
LaQinus a1bus,. have the property ot reducing blood sugar ot
normal individuals and diabetics. Other materials with hypoglycemic properties have been extracted from a wide variety
of plant tissues. 0011ip (59) extracted from clams aDd m&D7
plant sources, a substance, glucokinin, which produced marked
hypoglycemia whell injected into rabbits, While Little, Levine
and Best (1'8) found an insulin-llke substance in the disinte-

gration products of killed bacteria. Most of these preparations
were usually toxic to the liver, which is probably

wh¥ they

had a hypoglycemic .ffect.
Kassall, ReTle and Fing (106) isolated a hypoglycemic

compound from the unripe "ackee", the fruit of a plant, Blighia
sapida. 1his

com~ound,

which seemed to be a

called Bypoglycin A. Anderson ! l

~

~oly~e.ptide

was

(6) and Ellington, Hassall

and Plimmer ('78) determined that the hypoglycemic acti vi ty was

due to an amino acid. whose structure is giv8Jl in Table II.
A second h¥poglycemic compound has also been isolated from
Blig4ia saRida and the name hypoglycin B was given to it (104).
It is a gollPeptide composed of bypoglycin A and glutamic acid.
A new era of h3pog1ycemic oral compounds began in
1942 when Janbon, Chaptal, Vadel and Schaap (110) discovered
that 5-isopropyl-2-aulfanilamide-l,3,4-thiadiazole (also called

IP1D) possessed hypoglycemic properties. Although this compound
proved to be very highly toxic and fatal in some cases, it
opened an era of research on synthetiC hypos1ycemic compounds.
Since then, a wide variety of compounds have been examined for
hypoglycemic actioIl. These compounds can be characterized into
three classes; the thiadiazoles, the arylsulfony1ureas, and the
bibuanides.
Between 1942 and 1946, studies on the mode of action
of IFTD and other tniadiazoles in dogs and ratbits were made
by

~ubatieres

(139). From his studies came a general mechanism

for the action of the thiadiazoles. He found that IPTD does not

'I

Iii,

i',' i
,1
1

l~ :

produce hypoglycemia if the whole pancreas is removed, but mal

H
!'i

il

'I

",

}6
TABLE I
T1:U'J AR ILSULFOli ILUREAS

1~.N

-

C~

c=c
c-a

~C

-

HO~HCONHCH2(CH3)}

Cubutwn1de
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TABLJ'; II
GUA.NIDINE Arm OTdEH. HYPOGLIC.&Y1IC AGl!i.NT'-d

HN-C-NH..

2

II

2

Guanidine
,1.·.

NH

.,

1I~
Synthalin A
(n • 10)

Synthalin B
(n • 12)

Phenethy1biguanide

li1',poglycin A

Iiy,pog11'cln B

IFTD

I'
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do

80

if

little as one-sixth of the

a8

~1an4

remains. It is

most effective wheIl injected direct17 into the pancreatic
artery and acts independently of the nervous system. It also
lowers the blood sU6ar in inverse proportion of tne

sul~onamide

level of the blood and raises the respiratorJ quotient after
glucose administration. Chen, Anderson, and Maze (52) bave
re~orted

a

hy~og17cemic

action of

5-c7clo.pr~'pyl-2-8ultan11-

amido-l,3,4-thiadiazole in intact rabbits. However, since the
tniadiazoles were very toxic and sometimes hyperglycemic in
animals with severe alloxan diabetes (52), they were never
put into U8e.
Interest in the field was enhanced by the studies of

--

Franke, AChe1is, Betram et al. (2)(29)(91) on a new bypoglycemic

com~ound,

I-butyl-3-sulfonylurea (also called by ita

generic name carbutamide). It was found, however, to be toxic
and was withdrawn in October, 1956 from clinical trials. Since

then many hundreds of chemeally related compounds have been
st"adied for their hypogqcemic activity (49)(153).

The majority

01'

these compounds wel."e :found. to be too

toxic for human use, but three analogues of carbutamide t namely
tolbutamide,

chlor~ropam1de,

and metahexamide have been

subJected. to clil'lical atud.ies, and two of them, tolbutamide
and chlorpropamide are being extensively used for the treatment
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of mild, adult, diabetes mellitus. The third, aetahexamide, was
recently withdrawn from the market because it did not offer

aQy

important new beneficial features.

THE ARIL8ULFO.NX'LUREAS
Carbutamide (N-butyl-B'-sulfaD¥lurea, BZ .55, U 6987.
!nvenol or Nadisan) 1s a white crystalline substance wh1cb has
weak acidic pro»erties associated with the 8ulfanyl

~rou».

It

forma salts with alkalis and the sodium salts are easily
soluble in water. The estimation of tree carbutamide can be done
readily by diazotization and couplin6 reactions (59). The liver
partially detoxifies caebutamlde by acetylation and then the
compound is slowely eliminated by the kidneys. As with the
other sulfonamide. containing a p-amino group, carbutamide has
some antibacterial action and impaires the

t~roid

functioll (7)

(44).

The replacement of the p-amino 6rouP
by a

.etI~l

group gives rise to the

or

b¥po~l¥cemic

carbutamide

compound most

widely used in diabetes therapy, tolbutamide (.N-but,yl-N'-pto luenesulfonylure a, Rastinon, Orinase, D 860 or U 2(43). The
change of the substituted group on the benaene ring is respons1ble ror maD3 1mportant b10106 ioal differences. It is a white
crystalline solid with a melting point of 128.50

-

129.5°0.,
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and is

~ractieal17

insoluble in water, although it forms

soluble salts with alkalis. It can be readily dissolved in
acetone, chloroform, and alcohol. Various methods for the
determination of tolbutamide in blood and urine have been developed

(15o)(220)(2~1).

In man, tolbutamide is converted into freely soluble,

non-toxic, carboxylic acid (N-but31-H'-p-carboxy-phenylsulfonylurea) b7 oxidation of the p-metnyl substituent (140). N-butylN'-~-~ro~methylphenylsulfonylur.a.has

also been found in

blood in verr small amounts (204). Finall,., Mohni.k:e and
Wittenhagen (164) isolated from the urine of do.s a toxic
metabolite of tolbutamide, p-toluene.ulfonamide and another
compound which was later shown to be p-toluenesulfonylurea (105).
Scheme IX summarizes the .etabolic breakdown of tolbut ....ide.
The elimination ot tolbutamide i. done br the kidners,
mainly as the carboxylic acid (88). Tolbutamide, as contrasted
with carbutam1de, does not affect significantly the thyroid
function as assessed by 11 '1 studies (151). The abolishment of
the goiter-producing properties of the arylsul.fonylureas comes
trom the removal 01' the p-amino

~roup

(l48).

Chlorpropamide (N-propyl-N'-p-chlorobenzenesulfonylurea, Diabenese, P 601) is a white crystall1ne compound melting
at 121., - 128.,00 • Chlorpropamide differs from tolbutamide in
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SCHEJ..tE IX
THE METABOLISM OF TOLBUTAMIDE

9-t olylaulroD¥lurea
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N-butyl-N'-p-h3droxymethyl-

9 h enylsulfonylurea

p-toluene sulfanamide
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the fact that the p-Jaetiql group of' tolbut8Jl.1de is replaced
by

a chlorine atom and the butyl radical 1s replaced by propyl.
A single dose of olle gram of chlorprQpamide produced

a signif1cant hypoglycemic e:f'1'ect in normal subJects

~reater

than is produced by an identioal dose of tolbutamide (249). The
b1010g1cal "half-11fe" of chlorpropamide is about

}:>

hours,

which is approximately ten ti.e. than that of tolbutamide (225).
In

man. this compound. in contrast with tolbutamide. i8 pro-

bably not metabolized before excretion. fto definite chromatographic or ultraviolet absorption differences have been found
between the pure drug and that in serum or urine (117)(224).
Using the urine of dog8 treated with cblorpropaaide-s;5,
however, three d1fferent chromato6raphic spots were detected.
They were identified as tlle uncha.r:L&ed compound, p-chlorobenzene-

sulfonylurea. and p-chlorobenaene.ulfonaaide. The thre.

COJD..PQundl

accounted for ;0. 40. and 20 per cent res98ctively. In rabbits,
80 to 90 per cent of chlorpropamide was found to be excreted

uncb.an&ed (197).
The increased

~poglycem1c

activity of ohlorpropamide

as compared with tolbutamide is probably due to the higher
initial and more prolonged blood levels attained and not to
any inherent increased potenoy (67)(124). Tb¥roid function a8

assessed by plasma protein-bound

iod~e

levels and the thyroid

4;
uptake of radioactive iodine is not impaired by

cl~lorpropa

mide (217) •
Metahexamide (N-cyclohexyl-N'- (3-amino-4-toluenesulfonyl)-urea, Euglycin) is a very effective hypoglycemic
compound with a duration of action which is longer than that
of chlorpropamide. It is about as half as effective as chlorpropamide and

abo~t

five times as effective as tolbutamide in

producing sustained blood levels (124) • Dogs and rabbits
excrete 30 to 35 per cent of the administered metaheaamide dose
unchanged in the urine and 40 to 50 per cent as 3-a.m1no-4benzenesulfonamide (197). Since it was found that metanexamide
caused obstructive jaundice (89)(147), the compound has been
withdrawn from clinical studies.
It is generally agreed that in mammals the ar;rlsul.foqlureas produce hypot!)lycemia onll' when some functioning
pancreatic beta-cells are present. Roussay and Penhos (109)
showed that the presence of some pancreatic tissue is essential
for the hypoglycemic effect ot the arylsulfon,ylureas in the
same way that Loubatiere. (142) showed that this effect was true
of the aulfanylamidothiadiazoles. The arylsulfoD¥lureas reduce
the faatlng blood sugar level of intact and partially pancreatectomized or mildly alloxan-diabetic animals, but they do not
do so after total pancreatectomy in dogs, rabbits, rats, o.
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man

(l~;)(250),

nor in animals made severly diabetic with

alloxan •
.li1X'l.'lUlllliPA.l. Ie .i!;Jtl< i!,;~'.r:) OJ! AHY·U;U.LI!OI'f Y.LUhl!..,\;;i

The mechanism by wIucn tolbutamide and other h¥poblycemic a.L',ylsull'on'ylureas exert their h.fpoelycemic actioll is
still

dis~uted.

Like tolbutamide, the arylsulfonylureas are at

best poorly efi'eetive in the absence of functional .vanereatic
cells. Althoubh the evidence indicates

t!~t

~heir

administration

results in decreased paneL'eatic insulin (ltld) and increased
insulin-liKe activity in the .vancreatic vein (1'1'1)(187), l1J.a.D:3
metabolic effects which accompany arylsulfoLylurea induced
hypoglycemia are so different from tilose whier.!. accompaD¥
insulin indUCed hypoglycemia that some investibators postulate
the presence of major extrahepatic factors 01' arylsulfonylurea
action.
Tolbutamide and chlorpropamide added

!a

vitro, using

rat liver slices, have been found to d.ecrease ciJinephl'ineinduced glycogenolysis (238) and ketogenesis (37).

I',b.el . .

rat

liver homogenates were used., tolbutamide was found to alter a
number of

en~atic

activities, including at least one trans-

aminase (36), several D.l)N and TPN requiring systems (244), and
the 'phosphorylase redctivating system (2!:». Tolbutamide and
ehlorpro~amide

administered

!a

~

decreased ketobenesis (,8)
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(42)(12,)(1')4). Tolbutamide administered!!!. !.!!.2.t with the
efiect measured either!!:. !!!.2. or !avitro t has been found
(a) to decrease glucose output (210), (b) to increase the
synthesis o-r glycogen, fatty acids and protein, witilout tne
corres.,Vondinb extrahe1.Jatic effects seell with insulin (193),
(c) to decrease the conversion o-r fructose and t,alactose to
glucose (9)(190), and (d) to alter the levels 01' nwnerous
enzymatic activities, including increased activity of malic
enzyme (244).
Chlorpropamide may, under ceratin conditions,
slishtly increase the

~lyc06en

cOlltent of rat diaphragm, while
,

under similar conditions tolbutamide has no effect (.57). Chlor~ropam1de

also moderately depresses

glutamic~oxalacetic

trans-

aminase activity in the livers of well fed animals (207). These
scattered reports are compatible with the hypothesis that the
arylsultonylureas affect enzyme reactions which

de~end

upon

pyridine nucleotides as co-:f):ictors (243).
THE

GU~,IDrN~ DERIVA~IVES

In l')C:!b, lirau.k, liothman and Watiner (':JO) syntnesi2.ed
Synthaliu A (decamethenediguanide) after earlier re.,Vorts stated
that the administration of buanidine lowers the blovd-suear
concentration (240). A few diaLetic 'patients were t.J.eateu with
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synthaLin A, but it was subsequently proven to be quite toxic
producin~ histolo~ical

even in small doses (28),

chan6es in the

liver and kidney and all clinical use of the comj:Jound was
discontinued.
In 1'15'1, the llyp061ycemic af'fect of' pheneth,ylbit,:)uanide

(N'-beta-phenethylformamidinyliminourea hydrochloride, DBI,
Phenformin, Dibot1n) was described by Schapiro, Parrino and
.Freedman (214). TheJ investigated appro:x.1.mately two hundred
mono- and dl- substituted

a~l

and aromatic derivat1ves of

formamidinyliminoureas, and found that phenethylbi6uan1de was
a

hi~hly

active oral hypogl'ycemic compound in both normal and

alloxan-diabetic animals.
The mode of action of phenethylbit)uanide is dif:ferent
from that of tli.e arylsulfony1ureas as the compound produces
hypoglycemia in pancreatectomized animals (170), in severe
alloxan diabetes (234), and in patients with Juvenile or
insulin-deiic1ent type of d1alJetes (181). Pheneth'ylb1buanide
increases tlle b1u.cose uptake by the rat diaphra&ll
while the muscle e1ycoben content decreases (2)4).

!!l vitro t
A. max'ked

increase in lactic acid production and a decrease iu
consumption SUbbest that

pheneth'ylbi~uanide

oxy~en

atimu1ates anaerobic

glycolysis by inhibitiIl6 oxidative enzyme systems.
Wick, Larson and Serif (2)1), usinb aUipose tissue,
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have shown that phenetbylbi6 u&lide inhibits the oxidation
glu.co;::",~;,

o~

acetate and succinate and considerably reduces fat

synthesis. In man, the blood pyruvate and lactate levels are
raised (82) and there is no change in hepatiC vein glucose,
urea, pyruvate or lactate, nor in the oxygen consumption of the
liver (2,2). Lactate levels in the blood from the femoral
artery also remain unchanged. Hypoglycemia ca"not be produced
in normal humans by the administration of phenethylbiguan1de
(82), although with intact animals a decrease in tHe blood

su.gar concentration is easily produced. These results sugbest
trUlt the effects of'

.phenoth.Ylbl~uanide

are

lar~el'y

mediated in

the ¥oripheral tissues.
The tissue anoxia

sUb~ested

bJ this evidence may be

attributed to inhibition of cytochrome oxidase and succinic
dehydrogenase

{~2')(233)t

but a decrease in oxidative phospho-

rylation would have tL8 same result. Later work sUbbests that
biguanides inhibit the transfer of

ener~

rich phoswhate bonds

to adenosine diphosphate (126).
P.benethylbiguanide has also been found to

si~nifi

cantly increase the levels of serum inorganic pnosphate (215)
whereas the aryl.sulfonylw:'eas decrease the sel.'um. inorbanic
~hosyhate

(74)(97)(114)(225).

phenethylbit;;uanide inhibited

~111iams

!l

phos"phor'y~ase

~

(254) found that

phospl1otase, the

enzyme catalyzing the conversion of

phos~orylase

a to phospho-

rylase b. ifhe.i also :found that th.e compound had no eflect on
the activity of .vhosjihorylase a or ,phos,ithorylase b

01'

on the

enzyme de1Jhosphoj)I1os,Phorylase kinase which catalyzes the
conversion of phosphorylase b to phos,Phorylase a •
of phoslJ.horylase phosJ:)hotase

1£ ....v ...i ...tr;;;..o....

.tl.n

inhitition

woul<.l favor un increase

in tlJ.e a.mount of ,PLl.os,Phorylase a ,Present in the tissue. Since
phosphorylase a is believed to be the fvrm of the euz7&e active
in glycot!ienolysis t this could account for j,)art
in

gl.fco~en

produced by

01'

the decrease

'phenethylbi~uanide.

PHOCAUtE

Some thirty years ago it was noted t.tlat when procaine
hydrochloride (p-aminobenzoyldieth.Ylaminoethanol hydrocnlol'ide)
was useu as a pain killer, it had some the.t'apeutic value in
artihz'i tis, nervous disorders and certain othe,r conJ.i tions.
H.ecently t AsIan (10) has shown that procaine hydl'ochloride
decreases atherosclerotic lesions. It was also observed that
both the absolute and relative rise in the blobulin fraction
was the same for .:)atienta as fur control::.>. On tile other .hand,
the chanbes in the beta-blobulin fraction were more
In atherosclerosis, procaine chane:;;es the ratio
beta

~lobulins

in favor of the former, thus

01'

actill~

si~nlficant.

alj,lha to
like

he~arln.

when the cholesterol level of tile blood was measured as an
index of lipid metabolism .. it waH found. tllat treatment witll
procaine causes a rise of the mean values. ,;.slan (10) considered
this as basically desirable and interprets this as due to the
I!lobilization of cholesteI:ol rese.L"'ves t po!.)sibly as a result of
tne hydrotropic ation of procaine.
Smie;;el !!

!..!!..

(21(3) t on the other hand, have found

that a decrease in the blood cholesterol follOWS the aaministration of' procaine. Out. of 2'1

'patie~ts

treated with procaine

hydrocllloL'ide. 23 had a reduced blood cholesterol level. TIle
dr0.l:i in cholesterol ranged from 1.5 to 180 Jilt,;jlOO ml of blcaod.
Serum calcium concentration increased in 17 out of the

2~

patients treated with procaine hydrochloride.
Bucci and Saunders (46) have found that procaine was
an ef'fective inhibitor of monoamine oxidase and is clinically
effective in alleviating depression and reducillb psychotic
symptoms associated with schizophrenia.

~)rom

!E.

vitro studies

it. would ap'pear that p.I'ocaine is capable of' ini tiatine,. a clinical

,
•I

response by inhibition of three en:e:;yme systems: monoamine
oxidase, polypheuol oxidase, and choline esterase. Philpot (179)
has demonstrated that besides inhibiting monoamine oxidase and
polyphenol oxidase. procaine also irdlibits cytochrome oxidase.
Besides the inhibition of the above enzyme systems, 'procaine has

il,l

been found to have an antlhylJertenslve effect, reduclnt!. high
blood ,Pressures to normal. 'i'he llon-h.Y,vertensive ,Pa.tients were

found to have no significant changes in their blood pressure

(4~

:i

I,

I,

CHA1~EH

III

It is fairly v>rell establisheu. that tne cholt:ste.rol
concentration in the blood seL'um is a 'px'i.lllary factor in the
formation of atherosclerotic

~atches

in blood vessels. Barly

studies b.1 V,indaus (257) and Scnollheimer (212) ino.icatedtilat
in atherOSC..LeI.'otic aortas the cholesterol COl.-tent was t5reater
than that of normal ones. Both free

and

ester cholesterol were

present and the ratio of free to ester cholesterol

a9~roximated

that fOWld in the blood •
..Ha.rly invest.igators were able to induce atl.eL'osclerosis
in rabbits by putting them on cholesterol rich diets (113)(206)
(248). The use

o~

cholesterol as an atnero6enic stimulus (8)(242)

established it as the causative agent contained in the

~reviously

mentioned diets. The name atherosclerosis was biven by
i4archand (151) in 1905 to the lipid infiltration

o~

tile intima

which causes the amor'phous accumulation of tatt.y muterial. The
theories regarding its genesis are many and varied, but whatever
the tinal definition

o~

the initiation of atnerosclerosis may be,

there is little doubt that cholesterol is related to t.rus metabolic disorder in

SOHle

manner. The exact contribution of chole-

sterol to its etioloey, at the present time, is yet to be
I'lii
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clarified.
~he

best

ar~ament

for tne relationship between chole-

sterol and atherosclerosis is that the sterol is

alw~s

present

ill atherosclerotic plaques. The production of atherusclerosis in
animals by feeding

choles~erol

has also been interpreted as

evidence for its role in athero6enesis. The criticism leveled
a~ainst

this type of reasoning is that atherosclerosis in not

natural for these animals. liowever, this criticism could be
extended against maD3 other lines of research on human diseases.
A further implication of cholesterol as an important
etiological agent in the development of atherosclerosis comes
from the observations that human atherosclerosis is prominent
in clinical states

accom~anied

by hypercholesterolemia. Diabetes

mellitus, by virtue of its prevalance, is the most important
of these states. Liebow and llellerstein (134) have compiled data
froill literature on diabetes. It showed conclusively that a
definite increase in severity and incidence of atherosclerosis
accompanies diabetes. The exact cOL'relation between diabetes,
atherosclerosis and hypercholesterolemia is not clear. Man and
Peters (150) found that there is no relatiunship

betwe~n

severity of hypercholesterolemia, diabetes and atherosclerosis.
kabinowitcn (188), on the other hand, found that in Juvenile
diabetics the severit¥ o£ hypercholesterolemia was proportional

to the atherosclerotic patients found. Others have
same conclusion

re~ard1n~

co~e

to the

young diabetics (5b)(115). Iannacone

and Mollerstrom (112) and Liebo", Helleratein and jailer (135)

reported that d.iabetic atherosclerosis is related to sex, age,
and b.Yperteneion, but find

It
C~l

wo~ld.

.0.0

corL'elation with plasma lipids.

seem, then, tnat onl.)" in the cssa

o1~

"yount) <1i .oetics

any connection between serum cnolesterol levels and athero-

sclerosis be defined.

~hls,

bowever t still does not exclude the

fact tllat cholesterol. other than what is f"ound in tue blood,

can be excluded f"rom consideration in the

uevelo~ment

of athuro-

sclerosis.
Rosenthal (201) has sum:,\ed up the bulk 0:1.' evidence
relat1nt!; cholesterol to atherosclerosis. The conclusions VI'ere
based on a comparison ot diet t blood pressure, and atherosclerosis from data in a number of ,Populations. lfurther in.dication
came from the tact that groups

su.t1eri~

from malnutrition did

not have an incidence of atherosclerosis, while well-to-do
individuals ot the sawe group did. Data obtained during World

Yvan I

Rl1>1

11 .nave shown the efleets ot j:JOor nu.trition on athero-

sclerosis. The 6eneral trend of these reports has been that poor
\\d..rtime nutrition I.'esulted in decreased incidence of atlleroscle-

rosis in GermaD¥ (2j), Norway (6j), and Russia (114). However t
even in this data, there were many inconsistancics. In l!lnland t

for example, the total fat consumption fell continually between
1937 and 1947. In tne meantime, tne atherosclerosis death rate
rose from 1'138 to a peak in 1940, droklped until 1943, then rose
again throllgh l\)4rl (149). Again in Sweden, the total :.t'at intake
was constant between 1935 and 1939, bliLt the atherosclerotic

death rate rose during this period.
Keys (121) has sUGr::.;ested that dietary i'at and not
cholesterol is to be directly implicated in atherosclerosis.
Axamination of' dietary data of twenty two

co~~tries

shows that

tnis correlation is no better than that for other dietary
const1tuents (267)(268). It seems, therefore, that thero is no
connection between the serum cholesterol levels in normal or
atherosclerotic men and the amount of cholesterol 1n6ested by
these groups

(~5).

This conclusion, statistically arrived at,

could be questioned since it has been found. tha.t

'I

of

prefeedi~

cholesterol cuts down !a vitro synthes1s of cholesterol by 11ver

'I

slices (93)(98)(230).
Lande and Sperry (127) have examined tn. blood cholesterol, aort1c 11pid, and the degree of atherosclerosis in a
number of persons who died. There was an increase of aortic
11pids, but no increase in blood cholesterol
increase in the degree ot atheroscleros1s.

correspondi~

Simi~ar

to an

observations

have been made by Schonheimer (212) and Faber and Lund (81).

ii'
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stamlel.' and Katz (222) have shown that prolollt;,ed feedintS of
small amounts of cholesterol

Call

lead to severe stherosclerosis

without correspondiD6 elevations 01

ser~

cholesterol.

~orre

son (lb6) t on tlH) other hand. t found that the aVel'&t5e cholesterol
in arteries ot: coronary cases i& four times that; ot' controls t
and he l'eels that a detini te correlatilJn exists with blood

cholesteL·ol.
Recently t the Centl.'al 00mmitee of the Am.I.'ican Heart
Association released a statement

implicatin~ hi~h

fat diets and

high serum cholesterol levels in the proauction of atherosclerosis (50). Paterson (115), however has

dis~uted

the value of

this statement. He cites the work of Lande and Sperl:Y (12'7) and
his own long

te:r;'m

study on the cOlllparison 01' ante-mortem se.x'Wll

cholesterol level with tue severity of atherosclerosis postmortem in atherosclerotic cases (1'/6).
Cholesterol-i'ed rabbits rendereu. diabetic by inJection
of alloxan exbibit a marked lipemia and hypercholesterolemia,
yet showed a decreased severity

01'

atherosclerosis wheu compared

witn cholest.erol fed controls ('75)(15d). This alloxan ellect is
independent of sex,

wei~t

t

tne dura t10n 01' ex.veriment, or the

form in which cholesterol is fed. The results

o~

these experi-

ments have to be interpreted with causion since diabetes

~roduced

by alloxan cannot be extended to clinical diabetes mellitus found

in humans.

i
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The cholesterol content of the sera of patients on
cortisone therawy is

si~ificantly

increase in the severity of

elevated (3)(7j) and an

at~erosclerosis

in young cortisone-

treated persons has also been reported (}). Kobernick and
More (125) found this to be true also of cortisone treated
II'
I'

rabbits. Cook

~ ~

(61), on the other hand, studied relatively

tew animals and reported no statistically sibniXicant differences between the cholesterol and cortisone-sterol groups. The
relationship between Cholesterol and atherosclerosis, seems then,
not to be a Simple casual connection.

~~

workers have attempt-

ed to correlate cholesterol with one or another serum fraction
in the hope ot obtaining a better description of the metabolic
defect involved.
Lipids, other than cholesterol, have been known to
be involved in atherosclerosis by early workers in this
I:

tield (80)(122). A number of studies have shown that the cholesterol/phos~lolipid

"

I

ratio is elevated in cases of coronary

I

disease. AlthOugh the differences in ratios are quite striking,
so are tnose in cholesterol levels. Oliver and Boyd (173) found

~
,~

"

elevations in cholesterol/phospholipid ratios in coronary artery

III

disease in all age groups, however, the differences in plasma

t~I

cholesterol levels are also distinct. One criticism

or

the

cholesterol/phospholipid ratio is that the data obtained is

'I

J

rl

N

~

ji

~

'I' 'i

,,,'I,
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always

the coronary disease has started,

af~er

litt~beinb

known

of t,!:.\,e role the chwlges may p.Lay in initiatinb the disease.
A refinement of tlle

cholesterol/!>ho6pholi~id

rela-

tionship has involved the determination of these ra'tios in the
lipoprotein fractions of' the blood (205). The findiIltS in normal
patients and in patients with atherosclerosis indicate a shift
of' cholesterol from the alpha to the beta livoprotein with
advancin6

~e

and in certain hypercholesterolemic states. A

cooperative s:budy by the Advisory Council of the NatioLlal Heart
Association has studied both serum cholesterol and lipo9rotein
values in a

lar~e

number of cases over a laub period of time.

The majority opinion was that the lipoprotein measurament presented no advantaee over cholesterol analysis in

characterizatio~

of persons prone to develop coronary heart disease (16j).
~ceSB

is

alw~s

cholesterol or altered cholesterol metabolism

present in the active stages of human atherosclerosis.

it can be identified in t.be athel.'osclerotic lesions and can be
extracted. from them. Human arterial lesions can be produced
experimentally by its use with more exactness than the lesions
of many human infections can be produ.ced by the introduction
into susceptible animals of their

reco~zed.

causal agents.

It can be identified in and extracted from the experimental
lesions. Cholesterol t tllen, has to be conceded a. role in the

"

,

"

j
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etiology of atherosclerosis. Whatever side one takes in the

mw~

controversies within the field of atherosclerosis, all agree
that a general drop in serum cholesterol levels should be

J
I
I,',
\~

'·1;

,I

"

"

II

beneficial.

'il

I
'I:

I,:

It was stated before that atherosclerosis is very

'I~

,I

prominent in states accompanied by 4ypercholesterolemia. One
o~

these states, diabetes mellitus, is statistically the most

important clinical entity associated with disturbed lipid metabolism and a h3percholesterolemic
demonstratin~

The mass of evidence

ten~enc3.

i'

a marked incidence and severity of atherosclerosis

in diabetes is incontrovertible. Provided they have the disease
long

enou~,

diabetics will almost invariably be atherosclerotic.

warren (245) has found onlJ four patients free of atherosclerosis
among 484 autopsied cases with diabetes for five years or lonber.
This universality of atherosclerosis in diabetes is true for
young and old, female or male. Joslin (119) has stressed that
the frequency and severity of atherosclerosis in diabetes is
correlated with long standin6 uncontrolled
h3per~lycemia,

with concominant

~lycosuria

hy~erlipetu1a

and

and

h3~erchole-

sterolemia.
With the discovery of insulin and the oral hypoglycemic agents, the primary disturbance of diabetes mellitus,
hyperglycemia, has been controlled. There is, however, still a

II;i

I

Ii

,:!I
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question as to whether the

accomp&~i~

b3percholesterolemia

is reduced by these agents. It would be ver;t beneficial if the
h,ypogl.1cemic compounds controlled bot.h the e,lucose and cholesterol disorders. If the agents used for

controllin~

diabetes

do not at tHe same time control the cholesterol of the body,
only one metabolic disorder is remedied. What is more important
is that the cumpounds, although decreasing the blood glucose
level, do not increase the cholesterol level. The net effect
would be that of controlling one metabolic disorder while
encouraging the deveLopment of another metabolic disorder,
atherosclerosis.
The effect of the

hypo~lycemic

compounds on the chole-

sterol levels of the blood has not been studied very extensively.
The few results that are available are at variance with each
other. Carbutamide, an early hypoblycemic compound no longer
in use, was found to cause hypercholesterolemia (105). Tolbutamide has been variously reported. to increase or have no e1:fect
on the Cholesterol level of the blood (48). Recently tolbutamide
has been reported to decrease the beta-lipoprotein fraction
while havin6 no effect on cholesterol level (101). However,
this result was obtained with persons who had normal values £or
blood cholesterol. In the few instwlces where the patients did
have a higher t.l:lan normal cholesterol, the blood levels weL'e

slightly reduced (101). There has been no definite report as
to the effect of the hypoglycemic cUDl,Pounds on blovd cnolesterol
or on the biosJnthesis of cholesterol, with the exception of
insulin, which does lower the blood cholesterol (l?l).
Since many investigators believe that if the biosynthesis of cholesterol is controlled, the blood cholesterol
will also be controlled (93)(98)(231), the

investi~ation

described in this thesis will deal with the effect of hypoglycemic compounds: tolbutamide,

~henetr~lbie~anide,

chlorpropamide,

and metahexamide on cholesterol biosynthesis !!!. vitro. A comparison of these C0D190unds will be made with that of insulin.
If there is an effect of these

com~ounds

on the biosynthesis

of cholesterol t the elucidation of tl:l.e site of action will be
attempted.
Procaine hydrochloride, althout)h not a hypoglycemic
compound, will be included in the study since it does lower
both the blood pressu.re and tIle cholestdrol levels of the blood.

The m.aterials and methods used in the

investi~ation

of the effect of hypoglycemic COJ:lpowlds and ,a;>rocaine on cholesterol biosynthesis are described in this cha,t>ter.
MAl'ERIAl1)
~c~bator-Shaker:

The incubator-shaker used in tIle invest.ibation was
sp6ciaJ.ly constructed by Elmac

En~ineerint5

Comjllin.Y, ChicliuO,

Illinois. The shaker has a variable speed from
'per minute

~ld

2j

to 160 cycles

a variable stroke of a quarter to two inches.

The temperature is controlled by a mercury relay haviD6 an
accuracy of + 0.2 0 C from the set temperature. It also has a
water-sealed gable cover

throu~h

which any desired atmospnere

can be introduced. The incubation tray has places for sixty-six

25 or 50 mI. erlenmeyer flasks.
Animals:
The animals selected for use in tnese experiments were
Sprabue-Dawley female rats obtained from Abrams Small Stock
Breeders,

Ghica~o,

Illinois. 'rhe rats, wei . . . hing 8.,ih?roximately
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200 grams, were kept on a regular stock diet.

8acrificin~

was

done by decapitation.
Apparatus used in the preparation of tissue homogenates:
The rat livers were homogenized in a homogenizer of
the Potter-Elvehjem type which consisted of a smooth glass tube
and stainless steel pestle, with a gap of approximately 0.5 mm
between the pestle and the tube. The neccessary enzymes for
the biosynthesis of cholesterol were prepared by using a Spinco
Ultracentrifuge (Beckman Instruments Inc., Spinco Division,
Belmont,

Califo~nia).

Hypoglycemic compounds:
Tolbutamide (lot # CJO 11,584-2) and Metahexamide
(lot # CJO 12,860) was supplied by The Upjohn Company, Kalamazoo t
Michigan. Phenethylbiguanide (lot # 21) was supplied by U.S.
Vitamin Corporation, New York, New York. Chlorpropamide (lot

# 03-422-02EPD) was supplied by Charles Pfizer and Company, Inc.,
New York, New York. Insulin (Iletin, 40 U.S.P. units/ml with
an expiration date of January, 1962) was supplied by Eli Lilly
and Company, Indianapolis, Indiana. The insulin was stored in
the refrigirator at 4°C. until ready for use in the experiments.
Coenzymes:
Diphosphopyridine nucleotide (DPN, AR, lot # 50B7l3),
triphosphopyridine nucleotide (TPN, AR, lot # llB745) and

~

.Ii'!

~

I"

~.Ii

I

1
.1

.I

'1,'·

,I
1

adenosine triphosphate (ATP, AR, lot # 50B713) were obtained
from Sigma Chemical Company, St. Louis, Missouri. The cofactors
were kept under refrigiration at -10°0., until ready for use in
the incubation mixture.
Acetate-l-C 14 :
Sodium salt of acetate-l-C 14 was obtained from Volk
Radio-Chemical Company, Skokie, Illinois. The original specific
activity of acetate, 7.0 mc/mM, was diluted to 1 uc/20 uM by the
use of unlabeled sodium acetate (AR, lot # 90628) obtained from
Baker and Adams Chemical Company, East Rutheford, New Jersey.
The method of preparation was a carbonation of methyl Grignard
reagent and then hydrolysis. The acetic acid

WclS

isolated by

steam distillation, titrated with standard NaOH and evaporated
to dryness under vacuum. The radiochemical purity of the preparation was tested by carrier dilution analysis as sodium
acetate and silver acetate, and one dimensional chromatography
and radiautography of ammonium salt with n-butanol saturated
with aqueous 1.5 M NH • The minimum purity, as evidenced by the

3

above criteria was found to be 98 to J9 per cent pure. The
radioassay of the acetate-l-C 14 was done by combustion to CO 2
and comparisoll with HBS standard in an ioni zatioll chamber,
100 ± 5 per cent.
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FreR!£ation of liver ho.oienates:
Livers were obtained from rats weighing

a~vroximately

200 grams wbich were sacrificed by decapitation. The livers were

blotted, weighed. as wet weight, and ground gently at 100

rv. for

one to two minutes with 1.25 volumes of the Standard Buffer.
The preparation ot the buffer is described in the Appendix,
Part I. Unbroken cells and tissue debris were eliminated b¥
centrifugation at ?00xg for 15 ainutes in a Spinco Ultracentrituge. The entire process was carried out at OOC. The su~er
natant homogenate obtained was used as the source of enzymes
for the biosynthesis of cholesterol from acetate-l-C14 •

II·,
, I
I

The incubation mixture:
Each incubation vessel contained 0.5 al. of rat liver
homogenate (approximately 800 1It>. of liver), the

h,ypo~lycemic

compound or procaine in the specified amount, one al. of
Standard Buffer solution, and one ml. of substrate solution.
The substrate solution contained 1.8 micromoles of diph089hopyridine nucleotide, 1.8 .1cromo1es of triphosphopyrldine
micromoles of adenosine tri9hosphate, and 0.5
microcurie of acetate-l-Cl4 (as assayed by Tracerlab 60-16
nucleotide,

~.~

Windowless Gas Flow Counter) made up w1 th Wllabeled sodium
acetate to a total of 20 mlcromoles of acetate 1n each lncubatl0

li.i·I"

'1'1'11'

65
mixture.
Constancy of the liver homogenates:

In order to test the constancy of tne liver

homo~e

nates from preparation to preparation, the total cholestervl
of the homogenate was determined in each rat liver homobenate
tnat was prepared. Uholesterol analysis was done by the method
of Hermann (107). Before this procedure was adopted, two other
procedures were tried. One teChnique was based on a mOdified

i'I'

I'

ti~erry

~ebb

and

I

(221) cholesterol determination. The other

method de vended on a color formation of Cholesterol with FeS04
in acetic acid (131). Both methods proved less reproducible
and more cumbersome than the procedure of Hermann (107).

The color reagent for this method is made from a ten
per cent li'eCL • 6H20 in redistilled acetic acid which is mixea

3

with 150 ml. of re.gent grade H2S04 and made up to one liter.
The procedure for the determination of cholesterol in tissue
was a& follows. The Cholesterol was saponi1'ied and extracted
as described later in the chapter. A suitable aliq,uot of t,ile
petrolew:l et,her extract was pla.ced in colol.'imeter tubes and
tue ether evaporated to dryness. To tne

dr~

resisue

b

ml. of

tllacial acetic acid. was add.ed and then 4 mI. of tne color
rea6ent was

forcefull~

acetic acid by a 10 ml.

introduced directly into the
hJ~erdermic syrin~e.

~lacial

ThoroUbh mixinb

III
,I,

Iii
, I

was insured.

~'he

tubes were ali.ov.ed to cool to roum

tem~erature

and the color density was read or.. a Klett colorimeter using
I~

5b filter. The color is stable for at least two hours.

A standard curve, shown in F1eure I, is

bJ

pr~pared

addint,; from 0.1 to 1.0 Illl of' 20 mb% standard cholee tarol solution 1n glacial acetic acid. mou6h 61acial acetic acid is
added to make total vulwne 6 rul. Thl! color is then developed
as stated before. Prior to preparation of tn.e standard stock
solution, the cholesterol was purif'ied, as f'0110w8: I,:;) f:!)rams 01'
cholesterol (obtained from Eastman Chemical ?roducts, Inc.,
t;kokie, Illinois) was dissolved in 130 ml. of boiliJlltS 95%
ethanol. The solution was then filtered and cooled

slo~ly

at

about 5 0 0. 'rhe white crystals of choleste1.:ol which were formed
I

were removed by filtrationthroug.h Whatman if 42 filter paper.
'l'ht: recrystallized cholesterol was dried in a vacuum desiccator.

The purity of tLe recrystallized cholesterol was ascertained
by the sharpness ot the meltin6 point o£ the crystalS. The
standard solution was prepared fresh every 2 to
The constancy of the liver

homo~enate

~

weexs.

vreparations

is shown in Table III. The cholesterol content of six dif:f'erent
rat liver homObenates difl'ered only by 0.4

~7u.

therefore, that t,be h01Jlogenates prepared from
experiment were the same.

It followeu,

ex~eriment

to
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TABLl!; I I I

CONSTANCY OF

Expt.

Klett Heading

LIViSH

.tiOml()G~N ATES

Cholesterol
mg/&

1

2

3

4

5

b

Average
keadin&

12.b

144
136

11.,/

140

12.5

12.2

135
146
144

11.6
12.d
12.6

12.3

;

12.1

138
140
135

12.)
11.0

1;:.1

145
143
142

12.3
12.,
12.4

12.4

150
137

13.1

13~

11.0

12.2

138

12.1
11.5
12.4

12.0

1"
139

11.j
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Incubation:
Studies on the incorporation ot acetate-l-C14 into
the non-saponifiable lipid were carried out aerobically in the
Elmac metabolic shaker at }7°C. The oxygen was introduced into
the incubation vessels and used for flushing the C140 2 that .as
produced was delivered by ~ series of tyson tubing into each
individual vessel. The vessels, 25 al. erlenmeyer

flasks~

were

sealed by stoppers that had an inlet and an outlet to which the

ty~on tubins could be attached. The 0~402 was collected into
pyrex test tubes

containi~

10 per cent KOH solution. Atter a

two .nour 1llcubation period, the reactions were stopped by the
ad~ition

of 3 ml. of 15% KOB in 50% ethanol to each incubation

vessel followed by heati~ for 10 minutes at 37°0.
Isolation and extraction of non-saRonifiable liRids ana cholesterol:
The partiall,- saponified reaction mixtures were transferred to a 25 al., screw-capped culture tubes, and the reaction
vessel was rinsed with 3 al. of the alcoholic KOB solution and
added to the contents ot the culture tubes. Saponification was
completed by heating the titShtly capped tubes in water bath at
75-800 C., for 60 minutes. The saponified reaction mixtures were
extracted four times with 10 ml. portiolls of

li~ht

petroleum

ether (30-60°0 boiling fraction). This solutiun contains the
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total non-saponifiable lipid. It is composed of squalene, cholesterol,

a~l

cholesterol intermediates between squalene and

cholesterol, and. other non-saponifiable lipids.
In experiments where only the cholesterol was determined, the petroleum ether was evaporated to dryness iL a heavy
duty centrifuge tube. The residue was dissolved in 3 mI. of
acetone-ethanol (1:1 volume for volume),

an~

1.0 mg. of

~arrier

cholesterol in 0.5 JUl. of ethanol was adeled to this solution.
The ;-beta-hydroxy sterols were precipitated by the addition
of ? ml. of 0.5% digitonin (AR, lot # 51}480, obtained from
Merck, Sharp and Dohme Company) in

!J~

ethanol. After standine;

at room temperature for 16 hours, the digitollide precipitate
was recovered by centrifugation, washed once with 90% ethanol,
once with acetone, once with acetone-ether (1:2, volume for
vo~ume),

and tinally with petroleum ether.

In experiments where both the cholesterol and the
total non-saponifiable lipid were determined, on13 a suitable
aliquot of the petroleum ether extract was used :1'01: Cholesterol
determination.
Measurement of radioactivity:
014°2 was precivitated as the barium salt. The method
of recovery of 0 14°2 as BaC 140 depends on the nature of the
3
information desired. If tHe interest lies in a y,uantitative

71
yield, the best procedure would be to collect aLU titrate the
carbonate to bicarbonate;

follo~. . in~

which it may be precipitdted

as bariUll;, carbonate o.r the addit.ion of bariwn ion. If one,
however, is interested in only a semiquantitative ~ield or
precise specific activity, the C140 2 can be absorbed by an alkaline solution and then precij,)itated by BaC12 • Since the author
14
was interested in the specific activity of the 0 °2 obtained
from the incubation, the latter method was chosen. A suitable
aliquot, usually one milliliter of a total

of 5 mI., was
taken and precipitated by a l~& solution of BaG1 2 • The Bac l4 o,
vol~e

was then plated out Qn a pre-weighed # 42 Whatm.an filter paper.
After the weit;5ht of the preci'pitate was noted, the filter 'pclper
with BaC 14 , having a surface area of 2.84 em2 of plate4 mate3
rial, was ~laced Lnto a planchet and the C14 activity waS measu-

°

red with a Tracerlab 8C-16 iilldowless ]'low A.ssembl'y attached to
a Tracerlab Autoscaler (Tracerlab, Inc.,

Bos~on

, Mass). All

readings weL'e corrected for background and for self-absorption.
The measurable

activit~,

It differs from the actual

activ·',ty, lot becal.1se of self absorption of' the sWIlvle. rrhe
amount of self-absorption is given by the quotient 1/10 (5):
I
-y•

o

1 - e -uh
uh
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where u is the a'baorption coefi'icient, and h is mg/cm2 of the

~lated. material.

The

absorption coe1'.:r."icient for

(;1.1+

in

BaG0

3

has been eX.j,>eriItlentall,y found to have an average value of
0.29 (2&.. ). Using the self-absorpliion coef'ficient, the e'1uation

gi ven

OIl

the previous page is reproduced in l!'it..:ure II

&lld

is

called the sclf'-absor,1Jtion curve. The curve was used to make
self-absorption coz'~"ectiolls for all sam.~les of Bac14()3.

same

w~

The 3-beta-hydroxy sterol dibitonide was measured the
as BaC1403. Here, again, the problem of self-absorption

had to be considered. £\.lthout;;h a varioety of substances have
self-absorption curves suf.ticientl'y similar to that of Bao 140

3

to permit the use of the latter, a search of literature did not
provide any information as to the self-absorption of cholesterol
digitonlde. The self-absorption curve f'or cholestt-:rol dieitonide t
therefore, was determined.
Cholesterol-C 14 obtained from several incubations of
acetate-l-C14 with rat liver homogenates was pooled and 5.0
of carrier cholesterol wa!:J added for ever'y incubation vessel.
'L'lle final solution contained 42.3 mg. 01' cholesterol as determined colorimetric all" by the method 'previously described. The
Cholosterol-C14 solution was made up to a volwae so it contained
2 mb of cholesterol per milliliter of solution. Six dif1erent
ali'iuots (1,2,3,4,5, and 6 ml.) were taken and the cholestez'ol-
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C14 in each aliquot was precipitated by digitonin, ~lated and
cowlted as previously described. The results obtained are shown
in Table IV. The self-absorption correction curve (ldbure Ill)
obtained from the results in Table IV were used to make selfabsorption corrections for the cholesterol dieitonide. A detaile
,tirocedure for the construction 01' the self-absorption curve for
cholesterol digitonide appears in the Appendix, Part I.
14
]'or tue determination of the Cacti
vi toY of the total

non-saponifiable fraction, suitable
the

petrole~n

ali~uots

( 1 to 2 mI.) of

ether extract were measured in a Packard Tri-Carb

Liquid Bcintillation Spectrometer (Packard Instrument Company,
Inc., Chicago, Illinois). ;'l1aximum efficiency was obtained with
a photomultiplier tube voltage of 1020 v. and a discriminator
setting of 10 to 100 v. li'or all countint!J, who'ther gas flow or
SCintillation, a sui'ficient number of counts wao taken to reduce
the statistical error of cOWltinc to less than 5 per cent.
The RreRaration of the scintillation solution:
The composition of the

li~uid

scintillator which met

the criteria of tJ.1e hit;,hest counting e11iciancy, as sUt;;u..;ested by
Br&7 (42), was as follows: 60 gm of naphthaline (recrystallized

from alcohol, lot # NX 5) manufactured by

~atheson,

Coleman, and

Bell Co., East Rutheford, New Jersey and obtained from

Chica~o

Apparatus Co., Chicago, Illinois; 4 gm. of toluene-2,5,-dipheD¥1-

·1

:'
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'lABLE IV

i'

II;
'.1.1"

Weight of
cholesterol
m.g.

a/Wme;

Cholesterol
digiton1de
mg.

2

8.4

1050

4

16. '/

705

8

11.8

10

14.,

12

50.8

16.8

?J?J7
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oxazole (lJR), lot;;' 21002) and 0.2

gIa.

of l.4-d.i-2-(5-p.uell,yl-

oxazoyl)-benzene (POPOP, Scintillation Grade, lot d 2023)
obtained from J?ackard Ins·trument Co., Inc., Chicago, Illinois;
100 ml. ot absolute methanol and. 20 ml. of

etl~lene

glycol

dissolved in p-dioxane (Spectroquality Reagent, lot # DX 20>:J5)
manufactured by Matheson, Coleman and Bell Co., and obtained
from Chicago Apparatus Co., Chicago, Illinois, to make one
liter.
Ten milLiliters of this scintillation solution was
8.uded. to a counting vial containine; one milliliter 01' the active
petroleum etheL' solution that was to be deteI.'milled.

THE EFj'ECT OF HYJ?OGLYCEf4IC C0i!4R>UNDS AND PHOCAINl!; ON
CHOLESTEROL BIUSlNTHESIS

The mechanism b7 wbich the
their bypog17cemic action is still

exert

ar31sul~onylureas

dis~uted.

Though the

compounds are at best poorly effective in the absence of functional pancreatic beta-cella, it has

~een

observed that these

compounds affect other metabolic 94thways without the mediation
of insulin. Since cholesterol is thought to be associated with
atherosclerosis and since ATpercholesterolemia is prevalent in
diabetes mellitus, an investigation was undertaken to study the
effect of these compounds on cholesterol biosynthesis

~

vitro.

FACTORS AJ'FECTDG THE RATE OF BIOBI!iTHlSSIS 0.1 CHOLJjSTEROL

The factors affecting the rate of incor~oration of
acetate-l-C14 into cholesterol have been studied by Frantz and
Bucher (91). Since it haa a direct relationship to the problem
at hand, a discu8sion of theee factors would see. in order. By
omaission of i.1.ifi'erent coa.ponents. j'rantz and. Bucher (91)
obtained a maximum incorporation of acetate in the presence of
MgC1 2 , DPN. and nicotinamide. In the absence of added MgC1 2 or
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nicotinamide, the activity ot tue synthesized cholesterol was
very low, and in the absence ot both nicotinamide and DPN it
was reduced to near zero. In tne Vresence of nicotinamide,
ommiasion of supplementary DPN dro~ped the incorporation of
acetate-l-Cl4 to approximately 25 to 50 per cent ot the maximum
obtained with the complete system.

ThB neceesaity for

Ms~+ and Da~

tollows trom the fact

that both are needed in the biosynthesis of cholesterol.

Mg++

1s neceeseary for the activation of most enzymes from mevalonic
acid to squalene formation. DPH, in the reduced form (DPNH)
probably serves as a reducing agent in the conversion of dehydrosqualene to squalene. The reason that these two seem to be
lackin6 in the liver homogenate is probably because they are
lost in the preparative procedure. Bucher and li'rantz (91) found
that the maximum incorporation of acetate into cholesterol occurs
when the concentration of DPN is 0.0008 M and the concentration
of MgCl 2 is 0.0048 M.
The need tDr the presence of nicotinamide seem. to be
to protect DP.NB. from being .b.ydro17zed. back to DPN. The Dlax1.mp
Dlolarity of nicotinamide for the

~

vitro synthesis of chole-

sterol was found to be 0.05 M.
Since the catalysts in the reactions are enzymes, the
effect of pH is a great factor. It was recognized that the

!
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butfer strength empl07ed in the experiments was inadequate to
maintain the pH ot the concentrated homogenates at a constant
level. The optimal

~H

range

ap~ears

to lie between 6.8 and

7.2.

Because ot the· drop during incubation, the maximal incorporation in two hours was obtained when the pH of the but fer was
ini tially 7.4· to '7. o. The et't.eet ot

veu~yifj,b

the pH of the in-

c·v.bation mixtures is sho¥;u in Fit,ure IV. The initial and tinal
pH

of the inCUbation mixtures axe shown in the ii 6 ure.

The amount of tissue present in the incubation
mixture is proportional to the activity obtained in cholesterol.

In all instances, hit)her activities are obtained at high tissue
concentrations, and ne61igible

~ctivity

in dilute

'pr~'parations,

but the concentration at which the synthesis ~as maximal varied.
The incorporation of acetate-l-C l4 into sterol i8 aleo proportional to the time of incubation. After a slibht

del~,

the rate

was nearly linear for the first two hours and did Lot deviate
aven after four hours.
The effect of increasing the acetate concentration
upon the amount of cholesterol s¥ntheslaed is shown in

Fi~ure

v.

The incorporation curve reached a plateau at an acetate concentration of 8 to 12 micro.oles, whereas the allOunt oxidized
continued to rise. In teras of the available acetate present,
20 to 25 per cent was oxidized to CO 2 in the presence of 8 micro-
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moles of acetate, whereas only 12 per cent was oxidized when
the acetate concentration reached 20 micromoles.
Po~jak

!!

~

(185) have snown

not only DEN, but TrN and

ex~eri~ent~lly

that

as well are needed for the
max1~~ incor~oration of acetate-l-O l4 into ellolesterol.

The final

cv.uc~utl.·atil.illS

AT~

of substrate and C01'actors, as SUbbestec

0.1 li'rantz and Buchel.' 's (91) and Po..,Jak's (lB5) data., was chosen
to be 1.8 micromoles of DEN, 3.j micromvles of ATP, 1.8 micromoles of
(~ll

7. /{)

TPl~,

20.0 lIl1cromoles of acetate ill a ,PL.os,tihate buffer

conts.inin~

75 micromolC8 of nicotinamide (C.O;; .itt'),

12 micromoles of lIigC12 (0.0048 M) and 200 micI'omoles of phosphate (0.08 1\1).

EFlt"'ECT OF TOLBUTAJAIDE ON CHOLliSTEROL BIOSYN'!HESIS

Incubations were made with rat liver homo~enates,
acetate-l-c 14 , and tolbutamide in the presence of ATP, DPN, TP.N,
and Mg++

in a phosphate but':fer (pH 7.4) tor two hours at }?oc.

After the incubation, tile 3-beta hydroxy sterols were isolated
and counted as previously d.escribed.
The results in Table V indicate that tolbutamide
inhibited the incorporation of acetate-l-C14 into sterol at the
very low amount ot 0.05 micromoles. The maximal inhibItion was
between 4 and 20 micromoles. The specific activity is expressed
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TABLE V
EFFECT OF TOLBUTAMIDE ON CHOLESTEROL BIOSlNTHESIS

PART I

ConcentratIon
of tolbutaa1de
in micromoles
None

S~ecItlc ActivIty

of cholesterol
;
C/jA/g
180

1~5

2.0

124

4.0

92

20.C

9

0.1 microcur1es of acetate-l-l;14 was used in each incubation

vessel.
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in

elM!

of

cboles~erol

mg

of cholesterol and was obtained by

multi~lyi~

c/M/mg

digitonide by the gravimetric factor 4.18.

In order to find the relationship between the concentration of tolbutamide and the inhibition of cholesterol
biosynthesis, a study was made ot the effect of the concentration of tolbut.a.mide on the incor,Poration of acetate-l-C14 into
sterol. Ta'b1e VI shows that the in.h1b1 t10n

is proportional

to the amount ot tolbutamide present in the incubation mixture.
The maximum inhibition was obtained when the amount of tolbutamide was between 12 and 16 micromoles. Beyond this range the
biosynthesis of cholesterol was almost zero.
EJ'~'ECT

Oli

PHEliA~HY.LBIGUAl.. ID.E

ON

CHO~GTEROJ:'

BIOS:!.NTHESIS

The hypoglycemic compound that was studied next was
phenethylbie;uan1de. This compound is difierent from the arylsulfonylureas in that it produces its ily,Poglycemic ei'fect
without the mediation of insulin. It is active 1n alloxandiabetic animals and increases

gl~cose

uptake by isolated

tissues, while the arylsulfonylureas do not.
Although the

oom~ound

is diiierent in its

structu~.

and hypoglycemic action from the arylsulfon..rlureas,tlle ei'1.ect
of phenethylbiguan1de on cholesterol

biosy~thesis

is about the

same. Table VII ind.icates that when the amount of 'phenethyl-
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TABLE VI

EF1ECT 0]' TOLBUTAMIDE ON CHOLUSTEHOL

BI0SI~THls8IS

];JAR'!' II

ot tolbutamide

concentration

Sgecific Activity
ot cholesterol

None

1220

in micromoles

% Inhibition

elM/rAt!;

58.1

4

8

151

88.0

12

11

94.2

16

46

96.2

20

45

')6.2

1.0 microcurie. of acetate-l-C14 was used in each incubation
vessel.
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TABLE VII
EFld,;CT OF

p~l!.'frHlLBIGUANIDE

Concentration

ON CHOl.J!;STbatOL

of PUG

in micromoles

Speciric Activity
of cholesterol
c/M/mg

None

1610

BIUt~I""THESIS

" Il1hib1tion

1340

16.8

788

51.0

6

455

71.7

8

~2

78.8

10

~~

98.0

2

1.0 microcuries of acetate-l-C14 was used in eaoh incubation

vessel.

88

almost completely
inhibited the inC01"l>orat1on ot acetate-l-C 14 into 8'tEtrol. The

bi~uanide

was ten micromoles, the

effect of the amount of

com~ound

phenethylbi~uan1de

in the incubation

mixture was again pro,portional to 'I.;he decrease in radioactivity
in the sterol
amounts of

di~iton1de.

The degree of

'pheneth31bi.~ide

inh1bi~ion

of different

on the biosynthesis of cholesterol

compares favorably with that of tolbutamide as shown by
Fi..,ure VI.
Elil!JX;T Oi 'pH ON THE INHIBITION

In order to be certain that tne

iI~ibitory

erfect of

tolbutamide and phenethylb1 b uanide, and any subsequent effect
of other compounds that were investigated was not due to pH
cbant5e. of the substrate solution due to t .... e different WDOu.nts
of the comj,lounde used, pH measurementa were made on the different solutions. The pH of these solutions was measured by a
Beckman.glase electrode pH meter, Model G. Table VIII shows
that the buf'f'ering capacity of the standard .vhosphate buffer
was adequ,te to maintain the pH after the addi'tioll of tue
different concentrations ot hypog17cemic compounds or procaine.
A consideration of the effect of tile dif.ferent amounts of the
inh.i'bitors on the pH of the incubation mixtures is also in
order. After a two hour incubation time, the pH ot the homoSe-
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TABLE VIII
pH OF SUBSTRATE BOLlYl'IONS AND 11,CUBATluN f41XTURli2

Solution

pH of solution

pH of incubation
mixture after
incubation

Tolbutamide

7.40

6.95

Chlorpropamide

7.40

6.98

.llil

II,:
Iii
",

Metahexam1de

7.40

6.9~

i'

ill

I:;'

'III':

Phenethylbiguanide

7.34-

6.89

"'III
I

Ii

Insulin

7.40

7.00

,,'III
;"

Procaine

The amount of procaine was 50 micromoles, the amount of insulin
was 10 U.S.F. units. All other compounds were used ill the
amount of 10 LUicl:omoles.
,I
I

'1,::1!,

,

,:

, ,
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nates was measured

a8

before. The results shown in Table VIrI

indicate that the pH of the incubation mixtures atter a two
hour incubation was still in the ovttaal pH ranse (6.8 - 7.2)
required tor the maximal biosynthesis of cholesterol from
acetate-l-C l4 • fhe inhibitory eftect of tolb~tam1de and phenethylbiguanide, and a:D.¥ subsequent eli'ect . ! other compounds on
the biosynthesis of cholesterol, therefore, was due only to the
presence of the compound. in the incubation mixtures and not to

&nT pH changes which might be associated with the different
amounts of the inhibitors.
DIGITONIN AS THE .PllliCIPITATING AGEBT liOl{

CHOJ~Tb;hOL

The use of digitonin in the precipitation of cholesterol might be questioned, since it is not specific for cholesterol alone. It preci9itatea all '-beta hydroxy

st~rol

present

in the mixture. j'rantz and Bucher (91), whose incubation
procedures were followed, tested the sterol fraction recovered
as disitonide for identity and purity. The procedures followed
to test the hypotheSiS that the radiactivity was present as
cholesterol was (a) fractional crystallization, (b) pass8&e
through the acetate, (c) passage throv.gh the dibromlde, and
(d) a solubility curve. They found that the sterol preciv1tated
by

di~itonlde

from the incubation mixtures contained 97 per

92
cent cholesterol

and" per cent imjlurities and contained no

higher counting companions. Since the incubation procedures
that were followed were the same as that of Frantz and Bucher
(91), the purity of the cholesterol obtained from the incubation
mixtures was assumed to be the saae as obtained by thea. The
inhibitory effect, therefore, is on cholesterol biosynthesiS
and not on any other 3-beta hydroxy sterols.
Karab., McLaU&h1in and

Ri.~e1

(120) have described

a procedure of precipitation ot chole,terol br replacement of
digitonin by the

g~coa1de

The new reagent is more

tomatin as the precipitating asent.

s~ecitlc

tor cholesterol than is

disitonin. While the gl1coside does not possess absolute
speci.:Cicit;y, the sterol isolated from mce 15 minutes a1'ter
methyl labeled tritium acetate administration is free of hisher
counting com.panions. j'or amounts ot cholesterol 0.50 milligrams
or greater, quantitative precipitation takes place in les8 than
one hour at room temperature as compared with 16 hours tor
digitonin precipitation. Although tomatin would be a better
reagent to use, the preCipitates obtained could not be verr
easily plated for rounting. They were uneven and very

fl~.

--

Kabara et ale (120) also towld that the saponification of
esterified cholesterol was a critical step since too much alkali
decreases the

ac~uracy

of the cholesterol assay. The molarity
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of the KOH used in the hydrolysis of cholesterol esters by the
author was quite high, and therefore, the recovery of cb.olesterol
as the tomatin derivative would be very low. Because of this,
the use ot tomattn as the

precipitati~

reagent tor Cholesterol

was abandoned and all precipitations were made with digitonin.

In an attempt to localize the site of' action of the
hypo~l¥ce~c

compounds 1n the inhibition of cholesterol bio-

s.Y.tI.tLtesis, a study was made ot tile non-saponi1"iable lipid
fraction after incubation with tolbutamide. Although no one, as
yet, elucidated the completo nature ot this non-saponifia"ble
fraction, it i8 known that it contains squalene, post-squalene,
intermediates, and cholesterol. The data, shown in Table IX,
indicates that tolbutamide in concentrations of 0.05 to 20
micromoles inhil<lted the incorporation of acetate-I-C I4 into the
non-saponifiable lipid. Also, the magnitude of the inhibition is
clearly dependent on the concentration of tolbut.amide. The per.1

Ce.i:ltage of inhibition of the formation of' non-s&.p0nifiable lipid
sugbested an 1nterruption ot the biosynthesis of cholesterol at
an earls stage in the reaction sequence.
In order to obtain a clearer picture of this inhibition

a study was made of the distribution of radioactivit3 between

TAB1.& IX
.K]'FECT OF TOLBUTAMIDE ON NO.N-SAR)NIFIAIU...E; LIPID

Concentration
of tolbutamide
in micromole.

Uon-s~on1f1able

lipid
total CIM

Bone

5,080

0.05

4,000

2.0

,,240

4.0

2,870

20.0

1,690

0.1 microcuries of acetate-l-C l4 was used in each incubation
vessel.
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the

di~itonide

precipitable sterols and the other components

of the non-saponifiable lipid fraction. Tolbutamide, phenethylbit:,uanide, chlorpropamide, aetaheX8Jllide ( in the amounts of 10
micromoles) and insulin (0.1, 2.0 and 10.0 U.S.P. usits) were
incubated with rat liver homogenates and acetate-l-C l4 • After
the Incubation, the Cholesterol and the non-saJ:i0n11iable lipid
weI'e isolated and the activi ty determined. Table X shows that
both the digitonide precipitable cholesterol and the total nonsaponifiable 11pid were inhibited b¥

~ll

compounds, but not to

the same extent. The arylsultonTlurea compounds had a lesser
effect than either phenetbylbi b uanide or insulin on the incorporation ot acetate-l-C14 into the non-saponifiable lipid.
Furthermore, chlorpropamide aad metahexam1de had a lesser effect
on the biosynthesis ot cholesterol than the other compounds that
were tested. Insulin, even in the very low amount ot 0.1

u.s.P.

units completely inhibited the biosynthesis of cholesterol.
lioreover, 10 U.S.P. units of insulin had the same eflect on the
formation of the non-saponifiable lipid as phenetb¥lb1suanide.
When the amount of insulin was reduced to 2.0 and 0.1 U.s.P.
unita, the formation of tne
although it was never

h1~e~

non-8aponi~iable

than the

lipid was increased,

nOll-8apolll~iable

lipid

obtained when the arylsultoD¥lureaa were used.
In order to obtain tiJ.e etrect oi' the inhibition of
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TABLA X
DliEC';r OF Hl.POGLYC.haUC AGEHTS ON liUl,-SA?VNIJfLABLil; LIPID

Amt.

wa

None

S,Pec. Act.
of sterol

C/M/mg

NS)'

total

elM

10'0

10,060

Tolbutaaide

10

46

9,0;0

Ch1or,Pro,paaide

10

136

9,130

Metahexamide

10

139

9,720

ii
.1.

PheD.th31b1~uanide

4,610

10

Insulin (10 US.P un1 ts)

16

4,920

Insulin (2 USF Wlits)

21

6,890

Insulin (0.1 USF unit)

19

8,170

1.0 microcuriea of acetate-l-C14 was used in each incubation

vease1.

1]11
I.

I
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cholesterol on the decreased activity of the non-saponifiable
lipid fraction, the

cbolest~rol

digitonide was dissolved in two

milliliters of acetic anhydride and an aliquot of this was
cOUIlt •• together with the non-saponifiable lipid in a Packard
Tri-Carb Scintillation counter. Table XI shows that after the
subtraction of the

choles~erol

activity from the total non-

saponifiable lipid, the activity of the lipid fraction was still
lower than that of controls. The hypoglycemic compounds, thereinhibit the formation ot cholesterol but also
the incorporation of acetate-l-C14 into the non-saponifiable

fore, not

onl~

lipid otller than cholesterol. This indicated that the inhibition
was prior to the

fo~ation

of squalene.

I

LOCALIZATION OF THE SITE OF ACTION
The total non-saponifiable lipid fraction was partivioned into petroleum ether from the alkaline inCUbation mixture
after saponification with KOB. The aqeous resldue was then
acidified to pH 1.0 with

n~04.

After the solution had stood at

roo. temperature for one hour, the pH was readjusted to 10.0
with KOH, and the ne.tral C14-1abeled substances were extracted
with petroleum ether and the activ1t7 was determined in a
scintillation counter. The data, shown in Table XII, indicate
that there is a

lar~e acc~ulation

of the neutral petroleum ether

TABLE XI
DISTRIBUTION

O~'"

RADIOACTIVITY Bb"'TltEF.lf FRAGTIO.NB

HTpog17ceaic Agent

Sterol
C/W/mg

None
1'olbutam1d.e

i4Si'

liSM' - Sterol

1,550

10,850

9,305

&9

5,980

5,911

C/II/mg
ot sterol

"I,
"

Ohlol.·.t?l.' o,pamide

204

5,850

5,&46

lIletahexaraide

208

6,075

5,867

Phenetb¥lbisuanide

36

2,955

2,919

Insulin

24

3,075

3,051

All hTpoglycemic compounds were used in the amount of 10 micromoles, with the exception ot i!.!u1in which was 10 U.S.P. units.
0.5 microcurie. ot acetate-l-C was used in each incubation.

"II

;1 "
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TABLE XII
El'FECT OF lliPOGIJYCEMIC AG~.TE OIl NW'I(kAL-C14-COMR.>tlI~DS

H7pogl~cemic

Agent

AlIt.
WIl

Spec. Act.
of' sterol

elMlms

0.5 m1crucuries of acetate-l-C14 was

Neutral Cpds.
total elM.

used in each incuba,ion.
~as £low counter,
whilt: that 01' the neutral COIll,t.ioWlds by a scint1llation counter.

The activit3 of cholesterol was determined b, a

100

soluble fraction in the inhibited mixtures. It 1s presumed,
based on the findings of Lynen !!

!!:.. (142)

and

Popjak (183),

that this fraction 1s comprised of pre-squalene brunched chain
alcohol intermooiates, 1.e., the polyprenols. The data would,
then,

oJ the

sug~eat

that the inhibition of cholesterol biosynthesis

hy~oglycemlc

pyrophos~hate

agents takes place between lsopentenyl

and the formation of s<lualene. Attemptss at the

isolation and characterization of the h11:£hly active material
obtained from neutJ.'a.l petroleum ether soluble fraction were not
successful.
EllfEGT Oi' HY,POGLlCEMIC

AGJ.;;,NTf~

Fh.n.tb¥lbi~uan1det

ON CO

2

PRODUCTION FROM AG1!,'TATE

when incubated with rat liver

homObenates and Krebs cycle intermediates, bas been found to
inhibit a llu.m.oer of the enzymes needed :for the decarboxylation
of acetate (23.5). There are no reports, however, as to the effect
of the other hypo61ycemic com.;>ounds t namely th.e 8.r'ylsulfonyl-

4reas, ou t4e CO2 production bj rat liver homo.enates.
Tolbutamide was incubated with rat liver homoeenates
14
14
and acetate-l-C
and the C 0 produced waa collected and
2
determined as previously described. The data, Table XIII, ahow
that tolbl.1tamide, as did pheneth,.flbi~uanide, inhibits tLAe formation 01 014°2 by rat liver homogenates. The inidbitlon 1s
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TABLE XIII
EltFECT Oli' TOLBUTAMIDE ON CO

2

PRODUCTION OF RAT LIVEH

HOMOGENATES

Amount of
tolbutamide
in um.

None

148

4

127

8

116

12

84

16

50

20

43

0.5 microcuries of acetate-l-C 14 was used in each incubation.
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proportional to the amount

o~

tolbutamide used. A

com~arison

was made as to the extent of the inhibition of different hypoglycemic abents. Table XIV shows that tolbutamide, chlorpropamide, aetahexamide, and inaulin inhibit the production of'
14
(;
2 from acetute to a lesser extent than vhelletb.,yl'bi..;..u~3..uide.
That the hypoglycem1c com,pounds 1nh1b1tthe formation

°

of CO2 by rat liver homogenates seems to be reasonable since
they inhibit the f'ormation of D.P.NH and oxidize the DPNH alread1'
present in the incubation mixture

(24~).

The lack of DPNH would

result in the inhibition of the Krebs cycle and, therefore,
would decrease the production of

CO~

from acetate.

iallenfels, CreutzfB1d and Summ (243) have found that
tolbutamide and carbutamide in the concentrations of 10-1 and
10-2 inhibited the reduction of DPN to DP1~1l bj' hejiatic alcohol
and glutamic acid

dehydro~enase8.

The inhibition appeared to

be compet1tive since it could be reversed by
nucleotide concentration. The ox1dation

or

1ncreas1~

the

DPNll, on the other

hand, was increased by the a..c'ylsultoIl31urea deriva'tives. It

would seem then, that the arylsulfonylurea compounds possibly
inhibit Cholesterol biosynthesiS by interfering with the
formation of DPNH and oxidizing the DPNH alreadr present to DPN.

10;

jj;l' 1: ,t:;(';T

01' HtEOGlJi\Jl;;N1.iG

\';Ulli.POui~~

.ttA.'l' L.fv,U;H

liO:;tUG~l'AiJ.'~

Amt.
wa

None

Tolbutamide
Ch1orj/1.'opa.m.lde

01. (;02 r'nuDu\,;i' .1.,.ii~ 01-

Bl,)E!cii'ic Ac ti v 1 ty

C/MI.. BaOO;
550

10

159

10

;07

10

10
Insulin (10 U.B.P. w:dts)

251

0.5 lnicrom..xies 01' acetate-l-c 14. was used if. eac.b. incubation.

l04Since DPNH i8 needed in the formation ot 8qaalene from tarnesyl
and nerolidyl P7rophosphatea, or more accurately in the reductio
of dehydroaquzlene to squalene, the inhibition of cholesterol
biosynthesis by the ar.yleulfonylureas probab17 taxes place in
this step.

By inhibiting the formatiou of

D~~R

and oxidiziDb

~

D.PIUi that i8 all'eadl present, the a.r;ylaultonylureas 1>revent
the formation ot cholesterol trom its precursors. The bibh
accuaulation of activity in the

~olrp~enols

in all the intermediatea between isope.teD3l
and

would, then, reside
PJro~hos~ate

de~dros~ualene.

Boshell, ZahDd, and Renold (37), have found that the
administration of 3.0 grams of tolbutamide b7 mouth to fasted
tolbutamide-responsive diabetic patients significantly decreased
their circulating levels ot " ketone bodies". Tolbutamide in
concentrations ot 0.2 and 1.0

asia!

significantly inhibited

ketogenesis by l1ver slices rrom fasted rata. This tolbutamide
hepatic ketogenesis !a vitro was also demonstrated

effect

u~on

ill t1.a

'pI'esenc~

made

re~ardLnb

.of'

acetate as the substrate. .1'10 sUbgeEtion was

tLo mochanism of the tolbutamide erfect on

-

hepatic ketogenesiS in vitro. Their experiments failed to
indicate where and in what form the two-carbon fragments not
util1zed for aoetoacetute formation accumulate. Thoy have

105
sugsested that it is likelT to involve the activation of acetate
bT ••ter linkase with CoA and tn.n condensation ot two molecules

o! acetTl-GoA to fora acetoacetyl-eoA. The resalts obtained and
discussed in this chapter asre. with this h¥pothesis. Since
the formation ot alcohol

P7ro~0.phates

from acetate was not

impaired '01' tolbutamid.e or azq otl;,er hypogJ..yceaic compound.,

and in fact, an accuaulation of tbe.e polyprenols results, the
inhibition ot acetoacetate formation by tolbutamide probabl;r
takea ,Place b3 activation ot the aceta,te to acetyl-eoA. The

two carbon fragments not utiliaed tor acetoacetate formation
are, therefore, probabl;r utilized for the tormation of

po17-

prenola.

-

Phenetqlbiguanide, when added in vi1;ro to a c.1c10phorase type enz11Jle a7at.a, AU be.n found to inhibit the Krebs
cycl.

(2,».

Clo••J.' anaqais of this ettect has silown that the

co.~ound in concentratioDs of 10-4 ~ acta directly on the DPB
de»endent step. of oxidation of Citrate,

alpha-keto~l~tarlc

aCid,

fu.marate. oxalacetate, and p;rruvate. Tb.1a would. .ean tbat the
reduction of DPB to DP.NH that is accollplished b7 theae reactions

would be iapaired. Again, as in the case gf the arylsultoll¥lureaa
the aite ot

~e

inhibition is probablr in the reduction of

dehTdrosqualene to squalene, since DPBli 18 neltd.ed. for this

'I'll

I

reduction.
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Hollunger (108) bas found that guanid1ne and 87D-thalin
(decamet.L.eneguanid,1ne) 1:.l.t.u.bl ted the oxygen u,Ptake of m1 tochondria br inbibit;ing the mechani8Al that cOl.l!>lvs the oxidat1on
at the pyridine nucleotide-cytochrome e level with phospho-

rylation. In the course of the oxidative catabolism in the
organi. . , orthophosphate is esterifted with ADP to ATE. By this
reaction a maJor part ot the

ener~

released by the oaiaation

i_ eonaerve4 as eheateal .aerS7 available tor e.ergr-requiring
proce ••e. of the organ.18Dl. Guanidine

a:nd

srnt..b.alin, then, would

inhibit &DT reaction that needs A2P by UDoouplina

o~d&tlv.

phosphorylation. U.oa&r, i'a;rcho;ros and Hall (2,,) have found that
ph.elletbTlbisuanide a180 1nh1bi ta oxidat1 ve phos,Phor71ation. They
_usseat the po8sib1lity that the prim&r.1 action of' the co.pound
i8 on phospbor.rlation, inhibition ot oxidat1on being only
seeoDdar7 to the 1nh1bit1on of pnosphorylation. Such a possibility ia alao su,Pported by the effect of uncoupling agents, which
by freeing ox1dation tro. phosphorylation tend to reverse the
effect of phenetb71biguan14e on the tricarboxylic acid c701e.
There la, therefore, evidence to iDdicate that DPH-dopendent
oxidative phosphorylation is the principal site of action of
phenethylbiS1aanid.e.

irOIl

their results, they concluded that the

priaarl aite of action of

phenethylbl~uanide

was in the electron

transport aT&te. associated with 8uccl,nooxid.as., aore preciseJ..y

I'I!
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at a point between 8ucciniC

de~drogenase

and reduced cyto-

chrome c.
InhIbition of
i.n the lack. of A"1'P for

oxidativ~
t.ll~

.vho:3phorylation. would resu.lt

syntheHis of the two mevalonate

plloB.vhates and the polyprenol P7Z'0phos¥hates. The data, however,
ehow that these intermediate. are not inhibited by phenethylbibuanide. In ract, th. formation ot
is potentiated boY

do not

sup~ort

eth¥lbi~uan1de

~lTprenol p¥rophos~ates

.phenetL.ylbi~uanide.

The

~;e8u.lts,

there;fore,

the bypathesis that th, site of action of phen1s the

inh1bl~lon

of oxidative

~nos¥hurylation.

'fhis 1s true, at least, ill the 578tea that was used for the
experiment8. It is true that Ungar 11

~

(235) used a mito-

chondrial sTot •• for their experiments, while the author used
a combination of soluble, microsomal, and mitochondrial
preparation for his studies. RecentlJr We1nbach (247) has found

that when cytoplasmic preparations .ere used another mechanism
could phosphorylate ADP whell the oxidative ,Phos,P!lo.t'j'lation was
uncouj>led. He found that al'thoUfSh the oxidative phos,phor,ylation
W.J.S

uncou.pled, there was an increase in phosphoenolii;iruvate.

B7 tt.. e action ot a kinase, pho&,Phoenol'pyruvate can

'phos~b.or'ylat.

ADI' to A!fP. The phospho1"l'lation of Al'F br oxidative yhoSklhory-

lation, therefore, car, be bY'passed in non-mitochondrial

~re~a

rations. The results,then, do not contradict Ungar's bJpothesi8

jl
I
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that

pheneth¥lbi~uan1de

inhibits oxidative phosphorylation.

l'rocaine has been shown to deerease atherosclerotic
lesions (10), the Cholesterol level of the blood (218), and the
blood pressure ot hypertensive patients (45). Although procaine
is not a b¥poglycemlc compound .. it does, however, red.u.ce th4it
Cholesterol level of the blood. Procaine, therefore, was included in the studies of the e1'1'fotcts of certain compounds on
cholesterol biosynthe51s. Incubations were made with procaine

in the same way as was done with the h.;r].loglyceBdc COD1,poWlds.
The results that were obta1ned, shown in Table XV, indicate
that procaine does inhibit the biosynthesis of Cholesterol.

The inhibition is proportional to the amou.ut of procaine bJ"arochloride used. 1.be effect was not due to .pH ehanses due to the
1

different amounts of procnine hydrochloride as snown by

Table VIII. The effect of procaine hydrochloride on the incorporation of acetate-l-C14 into cholesterol is not as great as
t.b.at of' the

hypogl.rc(~m1c

compounds. A com.parison of the effects

of all compounds used in the investigation on cholesterol biosynthesis is shown in Jigure VII.

~herea8

the inhibition of

cholesterol bios3nthesi& was almost oomplete with 10 micromoles

ot the

hy~oglyc~mie

compounds, 10

.le~omole8

of procaIne
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TA.BLE XV
Dli'ECT OF mOCAIli.&; Oli 'lIfE Blu!3X'Nl'HEBIS OF CBOLESTJS.ROL

iulount of

procaine
i.u

WI.

Jone

opeo. Act.
oi' sterol

" Inhibition

elM/JAg
1664

10

20

552

~.8

50

~02

81.8

40

207

1:"7

0.5 :mierocuries of aeetate-l-c14 waR llsed 1n each 1ncubtttlon.

110

z
o
I-

100

-~-----------e-

80

-J:CD
z

60

IZ
LLJ

40

e

/

e

/'

e~

e-

u

a:::
LLJ

a..

20

10

20

INHIBITOR

30

40

50

(fLM)

FIGURE VII

IlII{)GLYC~MIC

COW?OC.NOO

Al~D P11.0CAI.m~

Open c1rcles- hypoglycemic compounds. Closed circles - procaine.
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inhibited the cholesterol biosynthesis b,y only 43 per cent.
BYen at high concentrations (50 .ioro.olea), procaine did not

oo.~letely halt the incor»oration of ~cetate-l-c14 into cholesterol b¥

~~t

liver

no~o6~nates.

'fhe <fbserved decrease in blood. cholesterol ai'ter
tu~ adm~stration

of grocaiue

JrIl."obablj d.uo to t:o.e :in.tU.b1 tion

41d~ochlor1a.

01'

is,

thereto~.,

cholesterolbiosYI.!tlieais.

The action of procaine and the

~vo~lycemic

compounds,

tolbutamide, chlorpropamide, metahexamide, and phenethylb1gunide,
on the biosynthesis of cholesterol have been investigated b,y
the use of rat liver homogenates, the necessary cofactors,
and acetate-l-Cl4 • The results show that the incorporation of
acetate-l-C14 into cholesterol is inhibited by all by~o~lycemic
compounds to
cholesterol

ap~roximatel3

the same extent. The inhibition of

bios~~thealR b~

procaine h¥droehloride, although

very significant, is mucn lower than that of the

b.Y~ogl'ycem1c

compounds.

The data also sbow that the inhibItion ot cholesterol
biosynthcsi!'S by the hypof>lyceL"lie eoopoul:l.ds tukes place between
the

18o'p~nt.ll31

pyrophosphate and the formatioD. of sq,utllene,

.\fos;;i tly at the red:llcti.Ort ntc,P 01: dehyd.1:'o5q,ua1ene. It 1 f'

112
~robab1y

due to the inhibition ot DP.NH formation

fro~

DPfi and

to DPN by the hypoglycemic compounds.
The inhibition of the Krebs cycle, as .aasured by C140 2
production, by phenethylbi~uan1de was confirmed. The data also
the oxidation of

Dl~H

show that the other h3poglycemic

com~und8

also inhibit the

production of CO 2 b3 the rat liver homoganates,
lesser 81tent than ~henethylbl~uanlde.

altho~l

to a

--

Tho data supports the theory of Boshell at ale (37)
that the two-carbon fra&ments not

uti~lzed

tor acetoacetate

toraatitJIl atter incubation with tolbutamide arc activated to

acetyl-Co.A. The inhibition of oxidative phosJ,J.b.or.rlatlon by
'phenet.iqlb1gua.n14e, as re,POrted b7 UD6Ar !!. !.!!.. (235), was not
obtaine4 in the s¥stea studied.
A'lI,P

07to~laamie ~hospUorrlation

ot

is probably responsiblo for the d1fferene!;: in results.
Procaine hydrochloride, which reduce. cholesterol

!'!!.2, has been tound. to inhlbi t cholesterol

blo81ntl ..esis

!a

!!!

vitro. The data, partial17, explains the lowering ot blood chole
eterol reported bj" other 1nvestigators.
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PAB!' I

IUTBRIAh.'> .AND Ml':THODB

lreR!Fatlon of the St!94'£4 Buffer solutlon:
The standard bu1':fer solutlon used in all incubatlona

-.. ,prepared

LCJ

follows: 11.514 g. of

K~P04 (\8.

Mallinckrocl t

Cheaical Co.), 1.815 g. of i.H2 P04 (AR, Baker and AdaJlaon Chemeal Co.), 0.978 I. of M6Cl2 .6H2 0 (AR, Ilallinor04t Chemical Co.
aDd '.664 5. of niootlnamide (lot # 3351, Nutritional Bloohemi-

cals), was made up to one liter with
water.

doub~

• glass dlstllled

tinal aolarit7 ot the solutlon was 0.08 K wlth

~he

re.peot to phosphate, 0.0'

and 0.0048 K with

rQ~peot

Beckman pH meter, was
~eaarat!on

~

with respect to nicotlnaaide,

to MgCl2.

~he

pH, as measured by a

tl.4.

of aelf-absorption curve tor cholesterol digitonide:

li'roll eata in

~aul.

IV t l>fl.6e 75 t

tl.t~

a,Pparent

specifio

aetlvlt7 (e/m/as) was plotted against sample welbht per unit
are. (.Ilt./cm2){~'1&\U'. VIII). The curve waa extra»olated to zero
thickneas and the "aaximum &vparent a!)eol!lc activity" was

obtained. Usi.r:.Lg this value t the 1'ractlon of' the "alUdmWil speci-

f1c actlvity" was calculated by dividing the speelrlc actlv1tr
ln

~able

IV b7 the "maxi&um &vvaL'ent s»eelflc act1v1ty (Table

XVI). The tract10n wau then

~lotted

against tbe weight per unit
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,(1650)
,,
'\

1000
Ol

800

E
"-

E

600

0..
U

400

4

8

12

16

20

mg/cm 2

fIGURE VIII
THE MAXIMUM

.APPABl~f

SPIDC!FIC ACTIVITY

III1
H

11II

I

il

I

JI
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TABJ.Jl: XVI
~B~ FRACTIO~

Oi TH]; SPECIFIC ACTIVITY

--

1050

o.~

705

0.43

11.8

16.8

0.2'1

390

0.24

351

0.20

14,

area (ag/CIIl2) and 'the .elf-absorption curve tor cholesterol
dis1ton1de that appears 1n l1gure III • .pase 76. was constructe4.

II
1.11'1'

II

TABU nIl
(Figure I~

Pa6- 61)

STANDARD CHOLESTEROL CUaVB

.•

Cholesterol

--"
2.0

4.0

6.0
8.0
10.0
12.0

net tReading
..........-.---.

10.0
18.0
20.0

p

12

13

27

12.5

29

28.0

49
50

49.5

68
64

&6.(;

93
83

91.0

il

11~

108
14.0

Avera&o

Ii

110.5

I

I

1~

138
156

II

1,,4.0

152

154.0

173
11,

17;>.0

191

19,

ii

I
Ii

192.0

1\,1,,1
11

'i '1'
1

~I

\1

il l

"1111
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.PART II
.u~ ECT

OF HI.POG.i.lICEdIC AGENTS AND .PROCAINb ON
CHOLESTEROL

BrOSI~THESIS

TABLE XVIII

Amount of'

tolbutam.id.e
1n WI.

None

4

Specific Act1v1ty
of' cholesterol

Average

1118
12}2
1270
1110

1220

Cl1A1Jaf5

510
486

498

504

163
161
141
139

151

522

8

12

7~

80
62

71

67
16

4442
4-8

46

50
20

47
48

42
43

45

:i)1

I11I

IIII

~, I

1,1,

I

::iIi,
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fABl& XIX
U~.ECT

OF .PHENETHYLBIGUANIDE ON CHOLE.<;TLtiOL BIOS!.NTHESIS

Aliount of

PUG (ua)

SpecIfIc Actlvitr
of cholesterol

C/¥/y

None

2

4

Average
•

1496
1545
1722
1675

1610

1345
1271
1285
1418

1340

869
708
768

788

,ii
II,)

726

4!;>5

455
402

455

448

8

330
349

35,

342

25
41
27
39

33

335
10

il
I

IIII

ill,II,

14?
TABL..:.: 1...X
E.F.'fl1NT OF arroGI,YCEMIC AGEffTS ON

NOl~-8APONIJ1I.tlBM

LIllID

AliD CHOLEST1'f:ftOL BIOBn"iTHESIB

Hypoglycemic Agent

NSL

0.1 a11q.

Average

cpa

Bone

Tolbutamide

1804
1588
1620
1411

1600

HSL

Total cpa (aliq.
x 10-1
16,060

934-

8??

85;

949

Ch1or,propamide

1081
1025
774-

915

781

Metahexamlde

948

98&

eno

972

9.720

4-61

4.610

984
P.benetbTlbiguanide

Insulin (10 units)

382
569
535
3lj7
532

461

4.920

5>8

Insulill (2 un1 ts )

41?
622
709

669
756

689

6,890
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TABLE XX

(CONTINUED)

Hrpoglyceaic Agent

.NSL

0.1 allq.

Averaese

cpDl

Insulin (0.1 units)

802
820
814

817

SSL

Total cpa {aliq.
x 10-1

8,170

832
14
.
1.0 micro.oles of acetate-l-C
was' used in each incubation.
The amount of inhib1tors was 10 aicromoles exc.~t where
spec1f1ed otherwise.
Spec. Act.
of sterol
C/M/ag
Bone
folbutamide
ChloJlpropa.ra1de
Met abexa.aid e
Pbenetbylb1guanide
Insulin (10 un1ts)

Average

10;;

1027

1030

50
41

46

10}
169

136

14"

1;5

139

26

21

2lt

12
20

16

149

B3,Pog13cemic Agent

.t-fbL

0.2 aliq.

Averat{;e

cgm

liS.u

Total cJ:& (ali",.
x 1/5
I

None

128;
1256

':1

1;01

u,505

459
44445?
474

4'18

2,';90

512
56?
577
527
51?

525

2 t C>25

547

2.7'5

Insulin (10 units)

51?
53;

525

2,625

Insulin (2 units)

559
578

509

2.84-5

13.29
1346

Tolbutamide

Ch1orpropaatde

54?

535

ACetahexamide

526

0.5 micro.oles of acetate-1-C14 was used in each incubation.
Unless specified, the amount of the inhibitors used was
10 microJlol.a.

I
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T.ABLI XXII
])I~~TRIBUTIO)f

OF RADIOACTIVITI B'i'WJ&a fHE i'RACfIOllS

B7pos1¥cwmic Agent

Sterol

Ave.

l{bL

Ay••

cpm/as

cpa/. .

of aterol
"

None

Tolbutamide

Chlor'pzoo,paa14e

1517
1;2'

10,957

10.850

75
63

69

5.%3
5,997

5,980

204

5,1';1
5,9't!>

5.850

215

193
....tah.x..14.

176
241

PhenetbTlb1guan1de

41

32
In8ulin (10 units)

10,14'

1;50

24

25

6,214
208

;,936

6.075

36

2,992
2,918

2,955

24

2,974},l?i

',015

0.5 microcurie. of acet ••-1-C14 was used in each incubatioa.

Unl••• s,peolt1ed, all .b1poglrcemic compounds ••.to \laod in

the aaount of 10 micro.olea.
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'fABLE XXIII
lU'i.iCT OF HlroGLYCRIC AGE.NTE 0.1 BEUTRA.li-C14-OOMFOU.MJS

B;ypogqcell1o Asent

Beutral O,pc:1s.
0.1 a~1quot

Ave.

cpa

.Neutral 0148.
total epa
(a11q. x 10-1 )

•

None

65

71

b8

61.8

678

07
Ohlorpropaa1de

893
922

927

910

9,100

990

9,900

1029

10.2'10

116't

11,EiA-O

1211

12,110

898
Insulin (10 units)

915

9'78
1065
1002
Pheneth¥lbiguani4e

1061
988

1070

991

i&etahexamide

1104

1213
1224
lOlb

l'olbutaaide

1189
11'9
1283

12"

Unle.s specified, tbe aaount ot b;1.P06Qo81l1e coapoUD4s was
10 micro.ol•••
0.5 microcuri•• o~ acetate-l-c14 was used 1D each iacubatAon.
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TABLE XXIV
DFECT OF TOlABUTAMIl)E Oll 002 .PRODUOTIOB 01 RAT LrVltR
HO?'~GrJ!iNA'r~

I

II
Average

MOunt of

tolbutamide
in um

hone

156

140
1?8

ll7
8

10&
126

12

85

148

127

116

84

16

59
41

20

0.5 microcurie. of acetate-l-c14 was used in each incubation.

I

,I

-.,1
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TABLE: XXV
lfiIl/}I.O'l OJ''

•

aIJ?OO.Llv~;'IC

.

COMPOliNDS 011 00 2 PRODUCT 10M 01 iUt
!trvllJi liJaQG.i!ll:iA1:ES

•• b

Hyj:los17aea1e Agent
n

_

-

R

.Ioae

Fhen.thylb16~nlde

-rol bu.t amide

140
C/il/ag'

Average

:aaC

561

-

...

5}3

550

166
152

15'3

'71
264

'07

Clllorpropaaide

29;
255

214-

Metahexam1<le

207

20;
Insulin (IO units)

2;~

293

207

251

Unless speoified, tne amoWlt of hypoglycemic COlil,POWlds that
was used 1n each incubation was 10 aicroaol •••
0.5 microourie. of ac8t&t8-1-o14 was us$d in each incubation.

TABLE

...

. . , I'

"

r

•

•

I

....

~

DOunt of
prooa1Ae
in ua
•

Bone

F

..

~lVI

...

....
Spec. Act.
of sterol
,

. . ..C/'ttI./q
..
16}9
1S89

10

979
908

20

,20
58!)

..
•

•

r

Avorage

.. . •
1664

94'
;,2

}O

}O5
}OO

302

40

159
255

201

50

166
14?

157

0.5 Mierocur1es of acetate-l-c14 wes used in each inoubation.

•
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